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Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder after Alzheimer’s disease, affecting approximately 0.3% of the total U.S. 
population, and its prevalence increases with age. Two neuropathological 
hallmarks of PD are the loss of dopaminergic neurons in the substantia nigra 
pars compacta, a region in the midbrain involved in initiating and sustaining 
movement, and the presence of cytosolic inclusions called Lewy bodies (LBs) in 
various brain regions.  LBs are enriched with fibrillar forms of the presynaptic 
protein α-synuclein (aSyn). Two autosomal recessive genes implicated in familial 
PD are PARK9, encoding the P-type ATPase ATP13A2, a lysosomal ATPase; 
and PARK7, encoding DJ-1, a protein with proposed antioxidant and chaperone 
activities. Understanding the biochemical mechanisms underlying the 
neuroprotective functions of DJ-1 and mechanistic details accounting for 
functional overlap between ATP13A2 and DJ-1 can provide insight into the 
cellular pathways relevant to PD pathogenesis.  
DJ-1 belongs to the DJ-1/ThiJ/PfpI superfamily, consisting of proteins that 




superfamily have shared characteristics including a conserved cysteine residue, 
a catalytic triad, and the ability to form oligomers. Whereas PH1704, a bacterial 
protease and a member of the DJ-1/ThiJ/PfpI superfamily, adopts a hexameric 
structure that is necessary for the formation of a catalytic triad, DJ-1 exists as a 
homodimer and apparently has a catalytic diad rather than a catalytic triad. A 
recent study has shown that DJ-1Δ15, a truncated form of DJ-1 (15 amino acids 
cleaved at the C terminus, resulting in the removal of helix H8,  has a much 
greater protease activity compared to full length DJ-1. The structure of DJ-1Δ15 
is similar to that of PH1704, which lacks a C-terminal helix corresponding to helix 
H8 of full-length DJ-1. We chose to focus on DJ-1Δ15 because it was not known 
whether this variant has the ability to form a hexamer, or whether such a 
hexameric structure is responsible for the observed protease activity (similar to 
PH1704). We analyzed DJ-1Δ15 via computer modelling using PyMOL to 
determine whether it can form a hexamer with favorable intersubunit interactions. 
In addition, we prepared recombinant DJ-1Δ15 and analyzed the protein via 
analytical ultra-centrifugation (AUC), native PAGE electrophoresis, and size 
exclusion chromatography coupled with multi-angle light scattering. Our PyMOL 
results showed that (i) DJ-1Δ15 can from a hexamer which may be stabilized by 
two inter-subunit interfaces, referred to as patch 1’ and patch 2 and, (ii) hexamer 
formation may lead to the formation of a catalytic triad involving residues C106 
and H126 from one subunit and E84 from another subunit. The full length DJ-1 
was unable to form the hexamer because helix H8 caused steric hindrances. 




representing species with different assembly states. There was evidence of a 
species with a molecular weight greater than that of the DJ-1Δ15 dimer. In 
addition the native gel data of DJ-1Δ15 showed a higher molecular weight 
species. Taken together, our results suggest that the DJ-1Δ15 protease activity 
may be due to the formation of an oligomer that is larger than the homodimer – 
potentially a hexamer.  
Analysis of the DJ-1 crystal structure revealed a previously undescribed potential 
ATP binding site that included two arginine residues, Arg 28 and Arg 48, near the 
oxidizable Cys106 residue. We therefore focused on elucidating whether DJ-1 
binds and hydrolyzes ATP. We found that our preparations of recombinant, 
human WT DJ-1 had ATPase activity that was lost upon filtration or 
ultracentrifugation. Analysis of our protein samples via sucrose gradient 
sedimentation coupled with immunoblotting revealed the presence of high 
molecular weight (high-MW) species immunoreactive with a DJ-1 antibody in our 
DJ-1 preparations. Additional studies revealed that the high-MW protein fraction 
of our DJ-1 preparations had ATPase activity and consisted of ring-like structures 
that could be visualized by electron microscopy. Furthermore, a DJ-1-positive 
high-MW complex isolated from these preparations by sucrose gradient 
sedimentation was shown via mass spectrometry analysis to contain F1 ATPase 
subunits, which are also known to assemble into ring-like structures, suggesting 
that the ATPase activity in our high molecular weight fraction might be associated 
with assembled F1 ATPase. Consistent with this idea, the ATPase activity in our 




azide or piceatannol, classical F1 ATPase inhibitors. Furthermore, we obtained 
evidence that dimeric DJ-1 may interact with purified E-coli F1 ATP synthase, and 
this interaction was apparently dependent on the presence of a reduced cysteine 
residue at position 106. These results imply that (i) F1 ATP synthase (in 
mitochondria) may be a target of the DJ-1 chaperone activity, and (ii) this 
interaction may be modulated by DJ-1 oxidation. 
Loss-of-function mutations in the ATP13A2 or DJ-1 gene have been shown to 
disrupt lysosomal autophagy and interfere with mitochondrial function and quality 
control. We hypothesized that dysfunction of either protein elicits neurotoxicity by 
triggering defects in autophagy coupled with an accumulation of dysfunctional 
mitochondria. To address this hypothesis, we investigated the functional interplay 
between ATP13A2 and DJ-1 in terms of their ability to protect neuronal cells 
against a PD related stress, methamphetamine (METH), an abused drug that 
disrupts autophagy in N27 dopaminergic neuronal cells. Our results showed that 
knocking down ATP13A2 or DJ-1 results in a buildup of LC3 II, an autophagic 
marker, whereas ATP13A2 over-expression reduces the accumulation of 
autophagic vesicles, termed autophagosomes. In addition, ATP13A2 or DJ-1 KD 
N27 cells showed a decreased rate of O2 consumption. Strikingly, the level of 
ATP13A2 mRNA was increased in DJ-1 knockdown in primary midbrain cultures; 
in contrast the level of DJ-1 mRNA was decreased in ATP13A2 knockdown in the 
same cultures.  These results suggest DJ-1 and ATP13A2 interact functionally in 




Overall, these studies have yielded insights into biochemical mechanisms of DJ-
1-mediated neuroprotection and of the functional interplay between DJ-1 and 
ATP13A2. Not only do these findings advance our understanding of 
neuroprotective mechanisms relevant to PD, but they also suggest new 






CHAPTER 1: INTRODUCTION 
1.1. Parkinson’s disease: an irreversible, progressive, neurodegenerative 
disease 
Parkinson’s disease (PD) is an irreversible neurodegenerative disease that was 
discovered in 1817 by a scientist named Dr. James Parkinson. In his “essay on 
shaking palsy”, Dr. Parkinson described the disease as characterized by 
involuntary tremulous movement and decreased muscular power[1]. Two 
neuropathological hallmark of PD is the loss of dopaminergic neurons in 
substantia nigra pars compacta, a region in the brain involved in initiating and 
sustaining movement and, the presence of cytosolic inclusions called Lewy 
bodies (LBs) in various brain regions [2, 3]. PD is the second most common 
neurodegenerative disease affecting approximately 0.3% of the total U.S. 
population and its prevalence increases with age, affecting up to 2% of the 
population over 65 years [4] and 5% of the population over 85 years old [5]. The 
U.S. government spent over $14 billion on persons with PD in 2010 [6]. It is 
estimated that the number of people suffering from PD is likely to double by 2040 
[6], and, concurrently, the cost of diagnosis and treatment will continue to rise. 
With the increase in lifespan due to improved health care, there is a need to 
understand the disease etiology at the molecular level and develop alternative 




pathogenesis by analyzing two PD related recessive gene products, DJ-1 and 
ATP13A2.  
1.2.  Symptoms, pathology, diagnosis and treatment of PD 
1.2.1. Symptoms and pathology 
Dr. James Parkinson designated the clinical symptoms of PD as difficulty 
initiating movements, resting tremor and rigidity [1]. Besides the typical 
parkinsonian motor dysfunction, PD patients present non-motor symptoms 
(NMS) including neuropsychiatric, sensory, autonomic, and sleep disorders [7]. 
These symptoms can lead to disability and a poor quality of life [8, 9]. Two 
neuropathological hallmark of PD are the loss of dopaminergic neurons in 
substantia nigra pars compacta (SNc), a region in the brain involved in initiating 
and sustaining movement and, the presence of cytosolic inclusions called Lewy 
bodies (LBs) [2, 3]. LB have been observed in different regions of the brain, 
including locus coeruleus, dorsal vagal, nucleus and anterior cingulate gyrus [10]. 
LBs are granular or globular inclusions present in the soma of affected neurons. 
Lewy neurites are diseased neurons containing granular material majorly aSyn 
filaments. PD  progression is classified into 6 stages based on the regions of the 
brain affected by Lewy neurites and LBs [11]. Stage 1-2, medulla and pons, 
stage 3, substantia nigra (SN), stages 4-6, hippocampus and neocortex [11]. LBs 
are mainly composed of fibrillar forms of the presynaptic protein, aSyn [12-14]. 
1.2.2. Diagnosis and treatment of PD 
The presence of LBs at autopsy is considered a confirmatory of a PD diagnosis 




response to levodopa [16]. Levodopa (L-DOPA) is a drug that slows down PD 
pathogenesis by controlling PD motor related symptoms, particularly 
bradykinesia [17]. L-DOPA penetrates the central nervous system via the blood 
brain barrier where it is converted to dopamine via decarboxylation by aromatic 
amino acid decarboxylase (AADC) [18] 
Other alternatives in the management of PD include catechol-o-methyl-
transferase (COMT) inhibitors, dopamine receptor agonists and non-
dopaminergic therapy (for example adenosine A2A antagonists) which may be 
used in conjunction with levodopa [19]. The above mentioned PD management 
therapies generally lose their therapeutic efficacy over time. Some of the 
reported side effects include recurrence of motor symptoms and dyskinesia [20]. 
In addition, although surgical intervention of patients with motor dysfunction, (e.g. 
via deep brain stimulation (DBS)) can have many benefits, it is costly and can 
cause complications such as infections [21].  None of the aforementioned 
therapies halts the underlying neurodegeneration, therefore there is a need to 
develop alternative strategies. Understanding cellular mechanisms that slow 
neurodegeneration in the brains of PD patients may suggest new therapeutic 
strategies.  
1.3. Idiopathic PD 
PD can be classified into two categories: (i) idiopathic PD, also known as 
sporadic PD; and (ii) familial PD. Idiopathic PD accounts for 90-95% of all PD 
cases and is caused by non-genetic factors that include aging (the greatest risk 




living in a  rural environment, and drinking  well water [22-24].  A number of toxic 
mechanisms have been proposed to play a role in PD pathogenesis, including 
mitochondrial dysfunction, oxidative stress, and accumulation of misfolded 
protein and damaged organelles due to dysregulation of proteasomal and 
lysosomal degradation pathways [25-28]. The focus of this thesis is on the role of 
mitochondrial dysfunction and dysregulation of lysosomal degradation 
(autophagy).  
1.3.1. Mitochondrial dysfunction and oxidative stress 
Analysis of the SNc and frontal cortex regions of post-mortem PD brains shows a 
decreased activity of complex I, an enzyme of the mitochondria electron transport 
chain [29-31].  In addition complex I subunits in PD brains show evidence of 
increased oxidative damage as a result of accumulation of protein carbonyls [32]. 
Complex I inhibition decreases mitochondrial adenosine triphosphate (ATP) and 
may cause a ‘leakage’ of electrons from the electron transport chain, leading to 
formation of reactive oxygen species (ROS), that damage mitochondrial DNA (mt 
DNA) and cause further mitochondrial impairment [33-35]. Oxidative stress 
occurs under conditions that lead to an imbalance between ROS production and 
antioxidant activity [22]. Dopaminergic neurons contain high level of ROS due to 
the presence of dopamine. Similar to other catecholamines, dopamine 
undergoes auto-oxidation to form the o-quinone form (Fig 1.1), a reaction that 
involves the generation of superoxide radicals [36]. In addition, dopamine readily 
is metabolized by tyrosinase and monoamine oxidase, two ROS-generating 




metabolism can damage mitochondrial electron transport subunits, thereby 
leading to further oxidative stress associated with mitochondrial dysfunction as 
part of a vicious cycle [37]. Because dopaminergic neurons have higher basal 
levels of oxidative stress than other types of neurons, they are more susceptible 
to pathogenic mechanism that further up-regulate ROS, including mitochondrial 
dysfunction. ROS are thought to elicit toxicity through oxidative modification of 
macromolecules and organelles [38-40]. As one example, ROS cause lysosomal 
destabilization, by disrupting membrane integrity, a process referred to as 
lysosomal membrane permeabilization (LMP).  
1.3.2. Lysosomal involvement in PD 
Lysosomes are involved in the clearance of long-lived proteins, including 
aggregated forms of aSyn, and the  removal of old or dysfunctional organelles 
like mitochondria [41, 42]. Previous studies have shown impaired lysosomal 
clearance in dopaminergic neurons in both sporadic and genetic PD patients, 
suggesting that lysosomal impairment may contribute to pathogenesis of PD [43] 
[44]. Mutations in lysosomal proteins such as glucocerebrosidase (GBA) and 
ATP13A2, a lysosomal ATPase are associated with PD [45].  These findings 
suggest that restoring lysosomal function could be a reasonable therapy for PD.  
1.3.3. Autophagy in PD 
Autophagy has been referred to classically as a process induced in cells to 
enable the degradation of intracellular components under starvation conditions 
[46, 47]. There are three types of mammalian autophagy: (i) microautophagy, a 




components for degradation; (ii) chaperone mediated autophagy (CMA), 
involving the targeting of proteins with a specific sequence motif for uptake into 
lysosomes with the assistance of the molecular chaperone, Hsc70 [48]; and (iii) 
macroautophagy (referred to herein as ‘autophagy’), a multi-step process that 
involves the sequestration of organelles and cytoplasmic components via the 
formation of a double-membrane-bound organelle called an autophagosome [48, 
49]. Autophagosomes fuse with lysosomes to form autolysosomes, wherein the 
intra-lumenal components are degraded by lysosomal hydrolases [50] (Fig. 1.2). 
In mammalian cells, the microtubule associated protein light chain 3 (LC3) is 
modified via a ubiquitylation-like system [51, 52] to form LC3-I and LC3-II. LC3-I 
is a soluble form generated upon carboxyl terminal cleavage of pro-LC3 [53, 54]. 
LC3-I is modified to a membrane-bound form, LC3-II, by conjugation to 
phosphatidylethanolamine [54, 55]. Importantly, LC3-II localizes to the 
autophagosome and autolysosomes and is thus a characteristic marker of these 
vesicular structures [56] (Fig. 1.2).   Defects in autophagy are associated with 
various diseases including PD [47]. Aggregated proteins and dysfunctional 
organelles that cannot be degraded via the ubiquitin-proteasome pathway are 
cleared from the cell via lysosomal autophagy [57]. Accordingly, dysregulation of 
autophagy leads to the accumulation of protein aggregates and dysfunctional 
organelles in PD [58].  
1.4. Familial PD 
To date, there are 28 distinct chromosomal regions that have been identified as 




5 % of total PD cases. Eighteen specific chromosomal loci, (referred to as PARK 
loci) have been identified. These loci are classified chronologically (PARK 1-18) 
(Table 1.1) depending on when they were identified [59].  
1.4.1. Alpha-synuclein (PARK1, 4)  
1.4.1.1. Genetics 
As mentioned above, aSyn is a major component of Lewy pathology in patients 
with sporadic form of PD [14]. Missense mutations in the  aSyn gene have been 
linked to familial PD. The following familial substitutions have been identified; 
alanine to threonine at residue 53 (A53T) [60], alanine to proline at residue 30 
(A30P) [61], glutamate to lysine at residue 46 (E46K) [62], histidine to glutamine 
at residue 50 (H50Q) [63], glycine to aspartate at residue 51 (G51D) [64] (Fig 
1.3). Duplication and triplication mutations increase the copy number of the wild 
type aSyn gene [65, 66]. Although some substitution mutants e.g. A53T form 
fibrils more rapidly than wild type aSyn, overall the neurotoxic effects of familial 
PD mutants appears to result from the formation of protofibrils rather than 
accelerated fibrillization [67]. Some of the substitution mutants appear to favor 
oligomerization though not necessarily fibril formation [63, 64]  Duplication and 
triplication mutations favor aggregation of the protein via mass action [68]. In 





1.4.1.2. aSyn function 
aSyn is a 140 amino acid protein that localizes to presynaptic terminals [70]. The 
aSyn sequence is subdivided into three domains: (i) an N-terminal domain 
(residues 1-67), consisting of seven imperfect repeats, six of which contain the 
conserved hexamer sequence KTK(E/Q)GV (Fig 1.3), this conserved sequence 
plays a critical role in the association of aSyn with phospholipid membranes [71, 
72]; (ii)  the non-amyloid-β-component of Alzheimer’s disease (NAC) domain 
(residues 61-95), consisting primarily of hydrophobic residues that initiate 
aggregation [73]; and (iii)  the carboxy-terminal (C-terminal) region (residues 96-
140), enriched with negatively charged residues (aspartate, glutamate) and 
proline residues (Fig 1.3). Truncation of C-terminal accelerates rates of 
aggregation [74-76], and truncated forms of aSyn are present in LBs [77].  
In addition, aSyn may be involved in regulating synaptic vesicle release [78-80], 
and the protein modulates synaptic transmission [81-83], dopamine (DA) uptake 
[84, 85], and assembly of the SNARE complex [86].  
1.4.1.3 aSyn degradation in PD 
Abnormal aSyn expression causes defects in cellular protein degradation 
pathways [42]. The ubiquitin-proteasome system (UPS) [87-90] and lysosomal 
autophagy [91-94] are involved in the degradation of aSyn. Phosphorylated aSyn 
(pS129) has been shown to be degraded via the proteasome [95, 96]. In addition, 
in vivo studies have shown that at high expression levels aSyn is cleared via 




nontransgenic mouse) aSyn is eliminated via proteasomal degradation [97]. In 
contrast, other studies have reported that overexpression of aSyn disrupts 
macroautophagy [98]. Accordingly, disruption of the UPS and lysosomal 
autophagy is predicted to cause accumulation of aSyn, leading to the formation 
of toxic aSyn oligomeric species involved in neurodegeneration. Targeting 
degradation pathways may be a reasonable therapeutic strategy for PD.   
1.4.2. DJ-1 (PARK7) 
1.4.2.1. Genetics 
Deletions and point mutations resulting in a loss of functional DJ-1 protein are 
involved in autosomal recessive PD [99]. A six exon deletion has been reported 
in a Dutch family, and a missense mutation resulting in the substitution of proline 
for leucine at residue 166 (L166P) has been found in an Italian family [99]. 
Additional  homozygous recessive, substitution mutations include M26I  [100], 
E64D [101], E163K  [102], A104T [103]. Other studies revealed a mutation in the 
DJ-1 promoter [102]. In addition, two polymorphisms encoding the substitutions 
R98Q [103] D149A [100], have been identified in the DJ-1 gene. 
1.4.2.2. Protein structure 
DJ-1 is a protein composed of 189 amino acids that is encoded by the PARK7 
gene. Data from gel filtration, sedimentation and x-ray crystallographic analysis 
indicate that purified recombinant DJ-1 exists as a homodimer [104-108]. 
Monomeric DJ-1 has eight alpha helices and eleven beta strands [107] (Fig 1.4). 




as proteases and chaperones [109], and its amino-acid sequence is conserved 
among many species [110, 111]. Shared features of proteins in this superfamily 
include a conserved cysteine residue in a “nucleophile elbow” strand-loop-helix 
motif [106], a catalytic triad (cysteine, histidine and glutamate/aspartic acid) in 
some (but not all) members, and the ability to form oligomers [106]. The 
oligomeric state of these proteins varies widely ranging from dimers to hexamers 
[106].   
The structure of the monomeric subunit of DJ-1 is highly homologous to that of 
the monomeric subunit of PH 1704, an intracellular cysteine protease from 
Pyrococcus horikishii, forms a hexamer  stabilized by two types of inter-subunit 
interfaces, referred to as patch 1’ and patch 2 [105, 112, 113]. Patch 1’ is 
analogous to the interface between the two monomeric subunits of homodimeric 
DJ-1 (referred to as patch 1), although the two interfaces are rotated ~90°with 
respect to each other. The structural features that lead to the presence of a patch 
1 interface in the DJ-1 dimer but a patch 1’ interface in the PH1704 hexamer are 
poorly understood. 
1.4.2.3. Functions of DJ-1 
Since its initial discovery as an oncogene [114], DJ-1 has been reported to have 
many other functions (reviewed in [115, 116] ). Here we review functions of DJ-1 
related to its ability to act as an antioxidant, molecular chaperone, transcriptional 





1.4.2.4. Antioxidant function of DJ-1 
Rotenone and 6-hydroxydopamine (6-OHDA), two known PD-related oxidative 
stressors, have been shown to up-regulate endogenous DJ-1 mRNA and protein 
levels and to induce translocation from the cytoplasm to mitochondria [117]. 
Oxidation of a cysteine residue at position 106 (C106) to the sulfinic acid (SO2H) 
facilitates translocation of DJ-1 from the cytoplasm to mitochondria [118-120]. 
Oxidized DJ-1 enhances cell proliferation by binding and inhibiting apoptosis 
signal-regulating kinase (ASK1) [121, 122]. Over expression of wild type DJ-1, 
but not familial mutant forms of the protein, protects neuronal cells from reactive 
oxygen species (ROS) [123], whereas down-regulation of DJ-1 sensitizes cells to 
oxidative stress [124]. DJ-1 protects against toxicity elicited by hydrogen 
peroxide (H2O2), 6-OHDA and rotenone by up-regulating the antioxidant 
molecule glutathione, whereas it induces an increase in levels of the heat shock 
protein 70 (HSP 70) in neuronal cultures expressing mutant aSyn [125, 126]. 
These results suggest that DJ-1 protects against various PD-related insults, and 
the mechanism of DJ-1 neuroprotection depends on the type of stress.   
1.4.2.5. A role for DJ-1 as at transcription regulator 
Under conditions of oxidative stress, DJ-1 has been found to regulate various 
genes at the transcriptional level [125, 127]. DJ-1 knockdown in the mouse 
NIH3T3 cell lines induce a decrease in the level of extracellular superoxide 
dismutase (SOD3), an enzyme that scavenges ROS [127]. DJ-1 regulates 




lipoprotein receptor (LDLR) gene [128]. In the cells exposed to oxidative stress, 
DJ-1 forms a complex with the sterol regulatory binding protein 2 (SREBP2), a 
transcription factor involved in cholesterol synthesis, and binds to the sterol 
regulating element (SRE) to stimulate the LDLR promoter activity [128]. DJ-1 
positively regulates of the androgen receptor (AR) transcription factor through 
binding to the same promoter region as PIAS-alpha, a repressor that inhibits 
androgen receptor transcription activity [129, 130]. Studies in yeast have shown 
that DJ-1 can directly bind to AR [131]. In addition, DJ-1 stabilizes nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2), a redox-sensitive transcription factor that 
regulates the expression of antioxidant and detoxifying genes in response to 
oxidative stress via the antioxidant response element (ARE) [132]. Although DJ-1 
averts the formation of a complex between Nrf2 and Kelch-like erythroid cell-
derived protein-1 (Keap1), a negative regulator of Nrf2 [133], there is currently no 
evidence that DJ-1 binds directly to Nrf2 or Keap1, and thus the mechanism by 
which DJ-1 stabilizes Nrf2 has yet to be elucidated [134]. In contrast, other 
studies have reported that Nrf2-ARE is activated in DJ-1 knock out (KO) mice 
[135]. Two more transcription factors regulated by DJ-1 are p53 and nuclear 
factor-кβ (NF-кB). p53 is involved in many cellular functions including  apoptosis 
and the maintenance  of mitochondrial homeostasis during oxidative stress [136]. 
DJ-1 has been reported to be both a positive regulator of p53 [136] and an 
inhibitor of p53 transcriptional activity under normal conditions [137] and 
conditions of oxidative stress [138]. Interactions between DJ-1 and Cezanne, an 




NF-кB is involvement in many cellular roles including cell survival [139] and the 
regulation autophagy [140]. These studies suggest that DJ-1 is an upstream 
regulator of various transcription factors.   
1.4.2.6. A role for DJ-1 as a redox-sensitive molecular chaperone 
The structures of DJ-1 and HSP 31, an Escherichia coli chaperone that is a 
member of the DJ-1/ThiJ/PfpI superfamily, are conserved [108]. Analysis of the 
DJ-1 crystal structure revealed hydrophobic patches with the necessary chemical 
and geometric features to bind non-native protein substrates [108]. DJ-1 acts as 
a redox-dependent molecular chaperone that inhibits aSyn oligomerization and 
fibrillization [141, 142]. One group reported that mutation of cysteine 53 
abrogates a low isoelectric point variant of the protein and abolishes the 
chaperone and protective function of DJ-1 [141]. In addition, two separate groups 
have reported that cysteine 106 oxidation is critical for DJ-1 to function as a 
chaperone against aSyn misfolding [142, 143].  Furthermore, DJ-1 has been 
reported to impede the aggregation of citrate synthase (CS) and luciferase [108].  
1.4.2.7. Role of DJ-1 in regulating mitochondrial homeostasis 
Mitochondrial dysfunction and oxidative damage are characteristic features of 
neurodegenerative diseases, including PD [144]. Mutations in genes directly 
linked to mitochondrial function, i.e. Parkin, PINK1, and DJ-1, have been 
identified in familial forms of PD [144]. Parkin is an E2-dependent E3 ubiquitin 
ligase [145, 146], plays a role in bioenergetics and mitochondrial quality control 




enhance its elimination by autophagy and regulates the levels of PGC-1α, an 
important regulator of mitochondrial biogenesis [148, 149].   PINK1 (PTEN-
induced putative kinase 1) regulates mitochondrial homeostasis via HtrA2, a 
mitochondrial protease [150],  regulates mitochondrial morphology in mammalian 
cells [151], and plays a role in recruiting Parkin to mitochondria of immortalized 
cells [152-154]. Loss or mutation of DJ-1 induces an increase in ROS levels, a 
decrease in respiration rates and mitochondrial membrane potential (MMP), and 
a disruption of the critical balance between mitochondrial fusion and fission [144]. 
Oxidative stress in M17 human neuroblastoma cells results in DJ-1 re-
localization to mitochondria, a phenomenon associated with protection against 
cytotoxicity [117, 118]. DJ-1 has also been shown to protect neurons from 
rotenone-induced oxidative stress and cell death [155-157]. Mitochondrial defects 
caused by deficiency or mutation of these three genes can be rescued by trio of 
the enzymes [158].  Mitochondrial fragmentation triggered by aSyn 
overexpression can be rescued by overexpression of wild-type Parkin, PINK1, or 
DJ-1, but not their functionally deficient mutants [159]. Recruitment of Parkin to 
depolarized mitochondria is influenced by oxidative stress of wild-type DJ-1 and 
not its mutant, C106A [160]. Elucidating the structure and function of this trio of 
enzymes will provide new avenues for developing therapies in PD. 
1.4.2.8. Role of DJ-1 as a protease 
As mentioned above, the Pyrococcus horikoshii 1704 gene product PH1704 




the assembly of a catalytic triad at one of the subunit interfaces (referred to as 
patch 2 above). DJ-1 has an additional α helix (helix H8) at the C-terminus 
compared to PH1704. A recent  study has shown that a truncated form of DJ-1 
(15 amino acids cleaved at the C terminus, resulting in the removal of helix H8) 
has much greater protease activity compared to full length DJ-1 [46]. In this study 
DJ-1 was proposed to act as a cysteine protease with C106 and H126 forming a 
catalytic diad. The C-terminally truncated form of DJ-1 (DJ-1Δ15) was found to 
accumulate in dopaminergic cells exposed to oxidative stress, leading to 
conclude that full-length WT DJ-1 is in fact a zymogen that becomes activated 
via a redox-sensitive mechanism [46].  
1.4.2.9. Impact of DJ-1 on lysosomal function 
Cells lacking DJ-1 exhibit an increase in dysfunctional mitochondria and 
mitochondria-derived ROS [144]. In turn, ROS accumulation can induce 
permeabilization of lysosomal membranes thereby leading to impaired 
autophagic clearance and recycling of cytoplasmic constituents, termed basal 
autophagy [144, 161]. DJ-1 is thought to indirectly regulate autophagy through 
the extracellular signal regulated protein kinase 1/2 (ERK1/2), a kinase involved 
in stimulating lysosomal degradation and inducing autophagy [144, 162]. A 
disruption in the autophagic mitochondrial clearance (mitophagy) results in a 
build-up of defective mitochondria. Accordingly, a loss of DJ-1 activity leads to a 




1.4.3. ATP13A2 (PARK 9) 
1.4.3.1. Genetics 
ATP13A2 is a P type ATPase encoded by the PARK 9 gene. It is located at 
chromosome 1p36 between two other PARK loci, PARK6 and PARK7 [163, 164].  
ATP13A2 is a 1,180-residue protein that contains ten transmembrane spanning 
helices [165] and is hypothesized to be localized to the lysosome.  P-type 
ATPases are characterized by their ability to undergo large conformational 
changes while pumping ions across biological membranes via a process 
involving ATP hydrolysis. Mutations in the PARK9 gene result in autosomal 
recessive PD, suggesting a role for the lysosome in neurodegeneration [166, 
167]. There are three genetic lesions that have been identified at this locus: (i) 
heterozygous mutations leading to truncation or in-frame deletion, identified in 
patients with Kufor-Rakeb syndrome, (KRS) [164]; (ii) a homozygous mutation 
encoding the substitution G504R [168]; and (iii) heterozygous mutations 
encoding T12M and G533R[168].  
1.4.3.2. Expression and localization 
ATP13A2 is mainly expressed in the dopaminergic neurons of the substantia 
nigra in the brain [164]. Other studies have reported that ATP13A2 expression 
peaks during neurogenesis [169]. Hypoxic conditions increase the transcription of 
ATP13A2, in HEK 293 and MN9D, dopaminergic cells [170]. Furthermore, high 
levels of manganese (II) and Zinc elevates expression of ATP13A2 [171, 172]. 




There are three ATP13A2 splice variants [173]. Variant 3 is retained in the 
endoplasmic reticulum (ER) where it is rapidly degraded [173]. ATP13A2 has 
recently been reported to localize to the outer membrane of amphisomes [174].   
1.4.3.3. Protein structure 
There are three alternatively spliced ATP13A2 isoforms expressed in humans 
[173]. Isoform 1 encodes a protein with 1180 amino acids consisting of 10 
transmembrane domains. Isoform 2 encodes a protein of 1175 amino acids 
[173]. The loss of 5 residues in isoform 2 compared to isoform 1 is the results of 
an in-frame deletion near the N-terminus [173]. Isoform 3 encodes a protein with 
1158 amino acids; compared to isoform 1, this variant has an in-frame deletion of 
117 bases, generating a highly diverse C-terminus [173].  My study will focus on 
isoform-1 of ATP13A2.   
1.4.3.4. Protein function 
1.4.3.4.1. Role of ATP13A2 in autophagy and mitochondrial clearance 
ATP13A2 is involved in the ATP-dependent transport of cations across lysosomal 
membranes [164]. The localization of ATP13A2 to lysosomal membranes may 
play a key role in modulating autophagy. A loss of ATP13A2 function has been 
shown to compromise lysosomal acidification, decrease proteolytic processing of 
lysosomal enzymes, and reduce the degradation of lysosomal substrates [175]. 
Because dysfunctional mitochondria are degraded via autophagy [144], 
impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a 




Expression of ATP13A2 protects mammalian cells from oxidative stress and 
dysfunctional mitochondria [177]. In addition, loss of ATP13A2 function in human 
fibroblast decreases ATP production rates, mitochondrial DNA lesions, increased 
maximum respiration and mitochondrial fragmentation [178]. Previous studies 
have shown that the yeast homolog of human ATP13A2 suppresses aSyn 
toxicity in yeast and that it can also protect yeast cells from manganese toxicity 
[179, 180]. These studies suggest a relationship between genetics and the 
environment as the cause of neurodegeneration [179]. ATP13A2 regulates 
lysosomal functions and thus suggesting that it might control lysosomal aSyn 
degradation and buildup of aSyn aggregation [175, 181, 182]. ATP13A2 is 
involved in trafficking aSyn to the lysosome via macro-autophagy [175, 181]. 
Other studies have reported that ATP13A2 enhances removal of aSyn from the 
cell via exosomes [174]. 
1.4.3.4.2. Role of ATP13A2 in aSyn clearance 
ATP13A2 has been reported to protect both yeast and mammalian cells against 
aSyn toxicity [179]. ATP13A2 may control aSyn degradation via lysosomal 
macroautophagy, thus preventing the accumulation of aSyn aggregates [175, 
181, 182]. Overexpression of ATP13A2 protects cells from mitochondrial 
fragmentation induced by aSyn [176, 178, 183]. In addition, ATP13A2 enhances 




1.4.3.4.3. P-type ATPase Ion transporter 
ATP13A2 shares sequence homology with P-type ATPases, a large family of ion 
pumps that utilizes ATP to transport ions across membranes in eukaryotes and 
prokaryotes [164] (Table 1.2). P-type ATPases are characterized by their ability 
to undergo large conformational changes while pumping ions across biological 
membranes via a process involving ATP hydrolysis. P-type ATPase is classified 
into five subfamilies; ATP13A2 is a type-5- P type ATPase, a sub family of P- 
type ATPase expressed only in eukaryotes. Although ATP13A2 is homologous to 
members of the P-type ATPase family, its ion specificity and biological function 
are unknown (Table 1.2). Dysfunction of ATP13A2 may lead to accumulation of 
misfolded or damaged polypeptides. 
1.5 Objectives of this thesis 
The above sections highlight advances in our understanding of DJ-1 and 
ATP13A2 neuroprotective activities. However, a number of key questions about 
the function of these two proteins remain unanswered: (i) what are biochemical 
mechanisms underlying the neuroprotective function of DJ-1? (ii) How does DJ-1 
suppress mitochondrial dysfunction? (iii) Do DJ-1 and ATP13A2 interact on a 
functional level to modulate mitochondrial and lysosomal function?  
This thesis addresses these questions by studying the formation of high-order 
oligomers by a C-terminally truncated form of DJ-1 in a cell-free system. We also 
explore a potential mechanism for DJ-1 protective effects against mitochondrial 
dysfunction through the characterization of an interaction between DJ-1 and E. 




mammalian mitochondria. Lastly, we examine the interplay between DJ-1 and 
ATP13A2 in modulating mitochondrial and lysosomal functions in neuronal cells 
exposed to PD-related insults. These studies will provide insight into molecular 
phenomena underlying PD pathogenesis, and they may suggest new 
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Figure 1.2 Macroautophagy  
Macroautophagy starts by the formation of a cup-shaped isolated double membrane that engulfs 
cytoplasmic protein and organelles. LC3 II (an autophagic marker), is bound to the membrane of 
the phagophore and autophagosomes and is present in autolysosomes that result from 
autophagosome-lysosome fusion. The cytoplasmic proteins and organelles are degraded by 












    
 
Amphipathic  region Hydrophobic  region Acidic region 
N C 
1 60 95 140 
A30P E46K A53T 
1  MDVFMKGLSKAKEGVVAAAEKTKQGVAEAAGKTKEGVLYVGSKTKEGVVH  50 
 
51       GVATVAEKTKEQVTNVGGAVVTGVTAVAQKTVEGAGSIAAATGFVKKDQL     100 
 
101     GKNEEGAPQEGILEDMPVDPDNEAYEMPSEEGYQDYEPEA  140  
Figure 1.3 The domain and amino acid sequence of human WT aSyn. 
(A) aSyn contains 140 amino acids composed of three regions: (i) the amphipathic N-terminal region 
spanning residues 1-67, (ii) the hydrophobic NAC region, spanning residues 61-95, and (iii) the acidic C-
terminal region, spanning residues 96-140. Six of the imperfect repeats contain the conserved hexamer 
sequence KTK(E/Q)GV (boxed region). The arrows point to the familial mutants. (B) Amino acid sequence 
of human WT aSyn. Familial mutants are indicated by blue asterixes. Adapted from Dr. Strathearn’s 




























Table 1.1 Familial PD-related genes. AD, Autosomal dominant; AR, Autosomal 
recessive. 
    
Symbol Gene Locus Gene  Inheritance  
PARK1 4q21-22 aSyn AD 
PARK 2 6q25.2-q27 Parkin AR 
PARK 3 2p13 Unknown AD 
PARK 4 4q21-q23 aSyn/triplication AD 
PARK 5 4p23 UHCL1 AD 
PARK 6 1p35-p36 PINK1 AR 
PARK 7 1p36 DJ-1 AR  
PARK 8 12q12 LRRK2 AD 
PARK 9 1p36 ATP13A2 AR 
PARK 10 1p32 Unknown Risk factor 
PARK 11 2q36-27 Unknown AD 
PARK 12 Xq21-225 Unknown Risk factor 
PARK 13 2p12 HTRA2 AD/Risk factor 
PARK 14 22q13.1 PLA2G6 AR 
PARK 15 22q12-q13 FBX07 AR 
PARK 16 1p32 Unknown Risk factor 
PARK 17 16q11.2 VPS35 AD 
PARK 18 3p27.1 EIF4G1 AD 




Table 1.2 A list of the P-type ATPase’s 
P-
type  
Gene  Substrate  Disorder  
P1B ATP7A Cu2+ Menkes disease (MD), Occipital horn Syndrome  
(OHS), Spinal muscular atrophy, distal, X-linked 3 
(SMAX3) 
P1B ATP7B CU2+ Wilson disease (WD), Possible genetic risk factor 
for Alzheimer’s disease (AD)and 
parkinsonism 
P2B ATP2B3 Ca2+ Early onset X-linked spinocerebellarataxia1 
P2C ATP1A2 Na+/K+ Familial hemiplegic migraine type2(FHM2), 
Alternating hemiplegia of childhood1(AHC1) 
P2C ATP1A3 Na+/K+ Rapid-onset dystonia parkinsonism (DYT12,RDP) 
Alternating hemiplegia of childhood 2 (AHC2) 
P4 ATP8A2 PS Cerebellar ataxia, mental retardation and 
disequilibrium syndrome 4 (CAMRQ4) 
P4 ATP10A2 ? Angelman syndrome (AS) 
P5B ATP13A2 ? Kufor-Rakeb syndrome (KRS) 
Neuronal ceroid lipofuscinosis (NCL) 
P5B ATP13A4 ? Specific language impairment (SLI),  




CHAPTER 2: QUATERNARY STRUCTURE OF A C-TERMINALLY 
TRUNCATED, PROTEOLYTICALLY ACTIVE FORM OF DJ-1 
2.1 Introduction 
DJ-1 belongs to the DJ-1/ThiJ/PfpI superfamily of proteins, members of which 
often have chaperone and/or protease activity. Shared features of proteins in this 
superfamily include a conserved cysteine residue in a “nucleophile elbow” strand-
loop-helix motif [106], a catalytic triad (cysteine, histidine and glutamate/aspartic 
acid) in some (but not all) members, and the ability to form oligomers [106]. The 
oligomeric state of these proteins varies widely ranging from dimers to trimers 
and hexamers [106]. Data from gel filtration, sedimentation, and x-ray 
crystallographic analysis indicate that purified recombinant DJ-1 exists primarily 
as a homodimer [184, 185]. The monomeric subunit of DJ-1 is highly 
homologous to the Pyrococcus horikoshii 1704 gene product (PH1704), a 
bacterial cysteine protease which forms hexamers. DJ-1 has an additional α helix 
(helix 8) at the C-terminus compared to PH1704. A recent study has shown that 
a truncated form of DJ-1 (15 amino acids cleaved at the C terminus, resulting in 
the removal of helix 8 has much greater protease activity compared to full-length 
DJ-1 [46]. This C-terminally truncated form of DJ-1 (DJ-1Δ15) was found to 
accumulate in dopaminergic cells exposed to oxidative stress, leading Chen et al. 




via a redox-sensitive mechanism [46]. Importantly, however, it is not known 
whether DJ-1Δ15 has the ability to form a hexamer, or whether such a hexameric 
structure is responsible for the observed protease activity.  
We hypothesized that human DJ-1Δ15 adopts a hexameric structure similar to 
that of PH1704. To address this hypothesis, we analyzed the quaternary 
structure of DJ-1Δ15 using PyMOL, Western blotting, analytical 
ultracentrifugation (AUC) and native PAGE gel electrophoresis. Our results 
suggest that DJ-1Δ15 can form an oligomeric species that is larger than a 
homodimer (potentially a hexamer), whereas full-length DJ-1 does not form a 
hexamer because helix 8 prevents a conformational change that is required for 
hexamer assembly.   
 
2.2 Materials and Methods 
2.2.1 Materials 
The bicinchoninic acid (BCA) protein assay kit was obtained from Pierce 
Biotechnology (Rockford, IL). The ECF substrate was purchased from GE 
Healthcare (Piscataway, NJ).  Coomassie brilliant blue R250 and SDS were 
obtained from Amresco (Solon, OH). Trizma base, 2-Mercapto ethanol, 
ammonium persulfate (APS) and glycine were purchased from Sigma-Aldrich (St. 
Louis, MO). Isopropyl-β-D-thiogalactopyranoside (IPTG) and ampicillin were 





The following antibodies were used in these studies: mouse anti human DJ-1 
(3E8) (Enzo Life Sciences, Farmingdale, NY. Clone), secondary anti mouse IgG 
conjugated with alkaline phosphatase (Promega, Madison, WI, USA). 
2.2.3 Preparation of the WT DJ-1 and DJ-1Δ15 constructs 
A cDNA encoding wild-type (WT) DJ-1 was amplified by PCR and subcloned as 
a BamHI – Xho I fragment into the vector pGEX-6P-1, yielding the construct, 
pGEX-6P-1 GST DJ-1, which encodes an N-terminal GSH S-transferase (GST) 
fusion with DJ-1 (GST DJ-1), by Dr. John Hulleman, a former graduate student in 
the Rochet lab. A cDNA encoding DJ-1Δ15 was generated via PCR using a 
reverse primer that included a stop codon after codon 174 and subcloned as a 
BamHI – Xho I fragment into pGEX-6P-1, yielding the construct, pGEX-6P-1 GST 
DJ-1Δ15. To develop a system for generating DJ-1Δ15 without the GST tag, 
cDNA encoding DJ-1Δ15 was  amplified by PCR using the reverse primer 
referred to above and subcloned as an Xba I – Hind III fragment into the vector 
pT7-7, yielding the construct pT7-7 DJ-1Δ15. The sequence of the aSyn-
encoding insert in each construct was verified using an Applied Biosystems (ABI 
3700) DNA sequencer (Purdue University).  
2.2.4 Purification of recombinant human WT DJ-1 and DJ-1Δ15 
constructs 
Cells of the BL21 (DE3) strain of Escherichia coli were transformed with DJ-1 
expression constructs by electroporation. To prepare GST-WT DJ-1 and GST-




μg/mL) at 37 °C, and IPTG was added to a final concentration of 1 mM. The cells 
were grown under inducing conditions for 18 h at 18°C, harvested by 
centrifugation, and resuspended in buffer A (25 mM KPi, pH 7.0, 200 mM KCl, 15 
mM 2-mercaptoethanol (2-ME)). The cells were lysed by the addition of lysozyme 
(1 mg/mL), incubated on ice for 30 min, and run through a French 86 pressure 
cell (p.s.i. > 1000) (Thermo Electron Corporation, Waltham, MA). After 
centrifugation (20,000 g, 20 min), the supernatant was applied to a GSTPrep FF 
column (GE Healthcare). GST DJ-1 was eluted in 250 mM Tris HCl, pH 8.0, 500 
mM NaCl, and 0.3% [w/v] reduced GSH. Fractions most highly enriched with 
GST DJ-1 were identified by measuring the OD280 and pooled. The pooled 
fractions were dialyzed against buffer A plus 2-ME (0.25 mM) to remove excess 
GSH. The overall protein concentration was determined with a BCA protein 
assay, and the fusion protein was cleaved with PreScission™ Protease 
(GEHealthcare, 16 h, 4°C, 1 unit protease:133 μg DJ-1). Untagged DJ-1 was 
separated from free GST and residual protease (which contains an uncleavable 
GST tag) by elution from a GSTPrep FF column equilibrated with buffer A. 
Fractions most highly enriched with DJ-1 were identified by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS PAGE) with Coomassie blue (R-
250) staining and pooled. The purity of the final protein sample was estimated to 
be approximately 95% by Coomassie Blue staining. 
To prepare pT7-7-WT DJ-1and pT7-7-DJ-1Δ15, the cells were grown to an 
OD600 of 0.6 - 0.8 in LB plus ampicillin (100 μg/mL) at 37 °C, and expression of 




(IPTG, 1 mM). The cells were grown under inducing conditions for 4 h at 37 °C, 
harvested by centrifugation, resuspended in  buffer B (50 mM 
tris(hydroxymethyl)aminomethane (Tris) HCl, pH 7.4, 100 mM NaCl, 5 mM 2ME), 
and lysed with a French pressure cell (p.s.i. > 1000) (Thermo Electron 
Corporation, Waltham, MA). After centrifugation, DJ-1 was partially purified from 
the supernatant by successive ammonium sulfate precipitations (70% saturation 
followed by 90% saturation). The pellet from the second ammonium sulfate 
precipitation was resuspended in buffer B, and the protein solution was applied to 
a diethylaminoethyl (DEAE) Sepharose (GE Healthcare, Piscataway, NJ) anion 
exchange column equilibrated with buffer B. Fractions in the flow-through 
containing DJ-1 were identified by SDS PAGE with Coomassie Blue staining.  
All purified DJ-1 samples were supplemented with glycerol (5%, [v/v]) and 2ME 
(2 mM), and aliquots (1-2 mg/ml) were flash-frozen and stored at -80 °C. DJ-1 
proteins were subsequently prepared for analysis by thawing followed by buffer 
exchange or dialysis (there was no additional freezing or storage of the protein at 
4 °C unless otherwise specified). The concentration of dialyzed DJ-1 samples 
was estimated using the BCA assay. 
2.2.5 PDB Files used for PyMOL analysis 
PyMOL analyses were carried out using the following Protein Data Bank (PDB) 
files: 1P5F, human WT DJ-1 [106]; 1G2I, PH1704 [112].   
2.2.6 Analytical ultracentrifugation    
DJ-1Δ15 (purified from E. coli BL21 DE3 expressing the pGEX-6P-1 construct or 




h at 4 ºC.  DJ-1Δ15 purified from E. coli expressing the pGEX-6P-1 construct 
interacts with E.coli ATPase subunits to form a high molecular weight complex 
(see Chapter 3). To remove this complex (and thus enable us to focus solely on 
DJ-1Δ15 self-assembly), the protein was centrifuged at 100,000xg for 2 h at 4 ºC. 
The supernatant was recovered and the protein concentration was estimated 
using the BCA Protein Assay kit. The protein solution was then analyzed by 
analytical ultracentrifugation (AUC) at the Purdue Biophysical Analysis 
Laboratory (BAL). DJ-1Δ15 purified from E. coli expressing the pT7-7 construct 
was dialyzed as above and analyzed via AUC without the sedimentation step 
described above. AUC was carried out at 50,000 rpm on a Beckman-Coulter 
ultracentrifuge, XLI (Beckman-Coulter, CA). Sedimentation was monitored with 
both Rayleigh Interference and absorbance optics. Protein (concentration, 0.5-2 
mg/mL) was characterized at 20ºC for 12 h in 50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl and 1 mM 2ME.  Sedimentation coefficients and apparent molecular 
weights, c(s), were determined using SEDFIT v. 12.43 [186, 187]. 
2.2.7 Size-exclusion chromatography with multi-angle light 
scattering (SEC-MALS) 
SEC-MALS analysis of DJ-1Δ15 was carried out at the BAL. DJ-1Δ15 was 
dialyzed in 2 L of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl and 1 mM 2ME (same 
buffer as AUC above). A solution of the protein (1-4 mg/mL) at 0.5 mL/min was 
applied onto a Superdex-200 column 10/300 GL (GE Healthcare) connected to 
an ultra violet (UV) absorbance detector, a refractive index refractometer, and a 




the column were determined using Wyatt’s Astra software, and the relative 
amount of each species was assessed from the areas under the chromatogram 
peaks 
2.2.8 SDS-PAGE and native PAGE      
DJ-1Δ15 (purified from E. coli BL21 DE3 expressing the pGEX-6P-1 construct or 
the pT7-7 construct) was dialyzed in 50 mM Tris, 50 mM NaCl, pH 7.5 for 16 h at  
4 ºC. The protein concentration was estimated using the BCA Protein Assay kit, 
and equal amounts of protein (3 μg) were analyzed via electrophoresis on an 8% 
(w/v) native polyacrylamide gel (no SDS or reducing reagent in either the sample 
buffer or the running buffer, and the samples were not boiled). Alternatively, the 
protein samples were analyzed via electrophoresis on a 12% (w/v) SDS PAGE 
gel. The non-denaturing gel was run at 4 ºC at 80-100V for 2-3 h, whereas the 
SDS PAGE gel was run at 22 ºC at 80-115V for 1.5 h. The gels were stained 
using Coomassie Brilliant Blue dye for 20 min at 22 ºC and de-stained using a 
solution of methanol, acetic acid and water (3:1:6), (v/v). Gel images were 
obtained and analyzed using a Typhoon imaging system (GE Health Sciences, 
Piscataway, NJ, USA). 
2.2.9 Western blotting  
DJ-1 samples were assayed for protein concentration using the BCA Protein 
Assay Kit, and equal amounts of protein were separated via SDS–PAGE on a 4–
20% (w/v) polyacrylamide gel. The proteins were transferred to a 0.2 μm 
polyvinylidene fluoride (PVDF) membrane, which was then probed with a primary 




secondary anti-mouse alkaline phosphatase-conjugated antibody (1: 6000). 
Chemifluorescence images were obtained and analyzed using a Typhoon 
imaging system (GE Health Sciences, Piscataway, NJ, USA). 
 
2.3 Results 
2.3.1 Full-length DJ-1 cannot form a hexamer due to steric 
hindrance involving helix 8. 
Helix 8 of full-length DJ-1 is missing on PH1704, a bacterial cysteine protease 
that is highly homologous to DJ-1 and has been shown to form a hexamer (Fig 
2.1). We hypothesized that the absence of a C-terminal helix on PH1704 as 
opposed to the presence of helix 8 on full-length DJ-1 could account for why 
PH1704 forms a hexamer whereas DJ-1 forms a homodimer.  To address this 
hypothesis, we overlaid models of the three-dimensional (3D) structures of full-
length DJ-1 and PH1704 ‘half hexamers’ using PyMOL. Analysis of the overlaid 
structures revealed that full-length DJ-1 is unable to form a PH1704-type 
hexamer because of steric conflicts involving helix 8 (Fig. 2.2A). 
2.3.2 The results of a PyMOL analysis suggest that DJ-1Δ15 can 
adopt a hexameric structure. 
The monomeric subunit of DJ-1Δ15 is highly homologous to the Pyrococcus 
horikoshii 1704 gene product (PH1704) [112]. Because DJ-1Δ15 lacks helix 8 
(Fig. 2.2B), similar to PH1704 which exists as a hexamer, we hypothesized that 
DJ-1Δ15 can adopt a hexameric structure. To address this hypothesis, a model 




terminal amino acid residues were deleted to generate a model of the DJ-1Δ15 
3D structure. Analysis of the model revealed that DJ-1Δ15 could form a closed 
hexamer (Fig 2.3). Formation of this closed hexamer was made possible by (i) 
the truncation of helix 8, and (ii) a 90° rotation between two DJ-1Δ15 subunits at 
the interface that is homologous to the subunit interface of the full-length DJ-1 
homodimer. The interfaces of the unrotated and rotated subunits of members of 
the DJ-1/ThiJ/PfpI superfamily have been referred to as patch 1 and patch 1’, 
respectively [113]. In the absence of the subunit rotation, DJ-1Δ15 dimers 
retained the patch 1 configuration and could only assemble to form an open 
hexamer (Fig 2.4). 
Further analysis of the closed DJ-1-Δ15 hexamer revealed that C106 and H126 
on one subunit were positioned at distances of 9.5 Å and 5.5 Å (respectively) 
from a glutamateresidue at position 84 of an adjacent subunit (E84’) (Fig 2.5A). 
This positioning of C106, H126, and E84’ implied that the three residues could 
potentially form a catalytic triad, similar to that of PH1704 in which residues C100 
and H101 are positioned at distances of 7.3 Å and 2.6 Å (respectively) from E74’ 
(of an adjacent subunit (Fig. 2.5B). The two subunits carrying these residues 
interact at a new interface, referred to as patch 2 [113]. 
2.3.3. Recombinant DJ-1Δ15, but not full-length WT DJ-1, forms 
high molecular weight species that are larger than a homodimer 
(SDS-PAGE/Western blot analysis). 
Based on our PyMOL results (see above), we hypothesized that DJ-1Δ15 could 




to DJ-1. To address this hypothesis, full-length DJ-1 and DJ-1Δ15 were analyzed 
by (i) SDS PAGE (denaturing and reducing) followed by Western blot analysis 
using an antibody that recognizes both DJ-1Δ15 and full-length DJ-1; and (ii) 
native PAGE (non-denaturing and non-reducing) with Coomassie blue staining. 
As predicted, purified DJ-1Δ15 had a lower molecular weight compared to full-
length DJ-1 due to the truncation of the 15 amino acids from the C terminus 
region (Fig 2.6). A Western blot showed the presence of high MW species in the 
DJ-1Δ15 sample (Fig 2.7). In contrast, the results of native PAGE analysis 
showed no significant high-order oligomer signal (corresponding to an oligomer 
with an apparent molecular weight greater than that of dimeric DJ-1) in lanes 
loaded with two different purified DJ-1 del15 samples (Fig. 2.8). Thus, the 
Western blot results suggest that DJ-1Δ15 forms higher molecular weight 
species, consistent with the results of our PyMOL analysis (see above), but the 
native PAGE data suggest that oligomeric DJ-1Δ15 is a minor species and/or is 
unstable under non-denaturing electrophoresis conditions. 
2.3.4 Recombinant DJ-1Δ15 forms high molecular weight species 
that are larger than a homodimer (analytical ultracentrifugation).  
The next experiments were designed to investigate whether DJ-1Δ15 consists of 
an equilibrium population of monomers, dimers, and hexamers (and potentially 
also trimers). We hypothesized that DJ-1Δ15 forms distinct species with different 
molecular weights. To address this hypothesis, DJ-1Δ15 was analyzed via AUC. 
Sedimentation-velocity analysis of a sample of DJ-1Δ15 purified from E. coli as 




presence of three species with strikingly different sedimentation speeds, 
corresponding to the DJ-1Δ15 monomer (1.8S), dimer (3.0S) and a high 
molecular weight species (5.2 - 5.7S) (Fig 2.9). Similar results were obtained 
upon sedimentation-velocity analysis of a sample of DJ-1Δ15 that was purified 
from E. coli as a GST-tagged protein (following expression of the pGEX-6P-1 
construct) and subsequently cleaved to remove the GST tag (Fig. 2.10). The 
smaller peak (1.1S) detected in the DJ-1Δ15 preparation E. coli expressing the 
pGEX-6P-1 construct might be a DJ-1Δ15 truncated species. The results further 
showed that the distribution of DJ-1Δ15 among the different species varied with 
protein concentration  
In additional studies, a DJ-1Δ15 (untagged) sample was analyzed via SEC 
MALS, a method that involves (i) the chromatographic fractionation of protein 
species according to molecular weight, and (ii) monitoring protein elution by 
measuring light scattering signals that increase with increasing molecular weight 
of the eluted species. The results showed the presence of peaks eluting earlier 
than the dimeric peak suggesting that DJ-1Δ15 formed species that were larger 
than a homodimer (data not shown). In summary, these data further support our 
conclusion from molecular modelling (PyMOL) studies that DJ-1Δ15 can form 
high molecular weight species. 
   
2.4 Discussion 
In this chapter, we investigated whether DJ-1Δ15 can form oligomers that are 




system. Our results suggest that DJ-1Δ15 has the ability to form high MW 
oligomers, including potentially a hexamer. In addition, the results of PyMOL 
analysis suggest that formation of DJ-1Δ15 hexamer may allow for the formation 
of a catalytic triad by bringing E84 from one subunit in proximity to C106 and 
H126 from another. Whether residue E84 is critical for DJ-1Δ15 to function as a 
protease remains to be elucidated.  
2.4.1 Full-length WT DJ-1 does not form a hexamer due to the 
presence of helix 8 at the C-terminus.  
DJ-1 belongs to a superfamily of proteins with the ability to form functional 
oligomers (chaperones and/or proteases.  Purified recombinant DJ-1 exists 
primarily as a homodimer [184, 185]. The monomeric subunit of DJ-1 is highly 
homologous to the Pyrococcus horikoshii 1704 gene product (PH1704), a 
bacterial cysteine protease which forms a hexamer. DJ-1 has an additional α 
helix (helix 8) at the C-terminus compared to PH1704.  The results of our PyMOL 
analysis clearly showed that full-length DJ-1 cannot form a hexamer due to steric 
hindrance involving this additional α helix. 
Full-length DJ-1 has been reported to exist as a zymogen that becomes activated 
as a result of the cleavage of the C-terminal helix via a redox-sensitive 
mechanism [46]. The results of computational and biochemical analyses 
suggested that DJ-1Δ15 has the ability to form oligomers that are larger than the 
homodimer, including a hexamer (discussed in greater detail below). Chen at al 
further predicted that the DJ-1Δ15 variant has an ‘unmasked’ active site involved 




the full-length zymogen into the proteolytically active form by enabling 
conformational changes required for hexamer formation, which may in turn be 
necessary for the assembly of a catalytic triad encompassing residues from 
multiple subunits.  The presence of helix 8 suggests that there is a selective 
advantage to having DJ-1 only exist as an active protease under specific 
conditions (e.g. high oxidative stress), whereas the zymogen design does not 
appear to confer a selective advantage on PH1704.  
2.4.2 Removal of 15 C-terminal amino acid residues facilitates 
formation of a hexamer. 
Our computational analysis via PyMOL showed that  DJ-1Δ15 can readily form a 
hexamer as a result of the removal of the 15 C-terminal amino acid residues. 
This truncation allows for a 90° rotation between two subunits, resulting in the 
conversion of the patch 1 interface to the patch 1’ interface. In turn, only DJ-1Δ15 
dimers with a patch 1’ interface can undergo self-assembly to form a closed 
hexamer (or trimer of dimers). In contrast, only an open hexamer could form 
upon the self-assembly of dimers that have not undergone a 90° rotation to 
generate the patch 1’ interface. An open hexamer would be predicted to have a 
relatively low thermodynamic stability because (i) it lacks inter-subunit 
interactions involved in forming a closed structure, and (ii) it may expose greater 
hydrophobic surface area (i.e. at the unclosed ends of the open hexameric 
structure) compared to a closed hexamer.   
Taken together, these data suggest that the formation of a DJ-1Δ15 closed 




absence of helix 8  and would involve a 90°rotation between two DJ-1 subunits, 
converting patch 1 to patch 1’ in each of the three pairs of subunits constituting 
the hexamer. Moreover, the formation of a DJ-1Δ15 hexamer would potentially 
allow for the formation of a catalytic triad consisting of Cys 106 and His 126 from 
one subunit and E84’ from an adjacent subunit at the patch 2 interface.     
2.4.3 Hexamer formation by DJ-1Δ15 may be necessary for the 
assembly of a catalytic triad involved in proteolysis. 
The results of our PyMOL analysis also imply that hexamer formation by DJ-
1Δ15 may be necessary for the protease activity of this variant because a new 
interface (referred to as patch 2) formed upon the assembly of a trimer of dimers 
may lead to the formation of a catalytic triad, in contrast to the catalytic diad 
proposed by Chen et al. [46]. Our results showed that closed hexamer formation 
by DJ-1-Δ15 brings residue E84’ from one subunit in proximity to the other 
residues of the potential catalytic triad, Cys106 and His 126 from another 
subunit. Similarly, the relative positions of the three residues were the same in 
patch 2 of the hexamer formed from unrotated DJ-1 del15 dimers (with a patch 1 
interface rather than a patch 1' interface (data not shown). Future mutagenesis 
studies will be aimed at determining whether the assembly of such a catalytic 
triad is responsible for the observed protease activity of DJ-1-Δ15. Previous 
studies indicated that the distance between the glutamate and cysteine in a 
catalytic triad is ~2.6 Å and between glutamate and histidine is ~7 Å [188, 189].  
Therefore the distances from E84’-C106 (9.5 Å) is larger than typical distances in 




of conformational changes associated with hexamer assembly, and these cannot 
be detected by PyMOL. Future research will be focused on exploring such 
conformational changes involved in hexamer assembly via molecular dynamics 
simulations.  
2.4.4 DJ-1Δ15 oligomers larger than a homodimer exist in solution. 
AUC results of DJ-1Δ15 suggested that large oligomeric species exist in solution, 
and the abundance of these species relative to the monomeric or dimeric protein 
is concentration-dependent. These results suggest that DJ-1Δ15 high order 
oligomers are in rapid equilibrium with the monomeric and dimeric forms. 
Furthermore, the presence of bands corresponding to large oligomers on an SDS 
PAGE gel (detected by Western blotting) suggests that these oligomeric species 
may be stabilized by covalent linkages. Future studies will be aimed at (i) 
characterizing the equilibrium distribution of large oligomeric forms of DJ-1Δ15 in 
greater detail, and (ii) identifying key intersubunit interactions necessary for the 
assembly of these oligomeric species. Because the levels of DJ-1Δ15 high 
molecular weight oligomers relative to the monomer or homodimer appear low 
compared to the predicted levels of PH1704 hexamer [112], we infer that the 
intersubunit contacts at patch 2 of DJ-1Δ15 may not be as optimal for stabilizing 
a hexameric structure compared to those of the bacterial enzyme. Future 
research will be aimed at addressing this hypothesis with a combination of 
computational and mutagenesis studies. If the hypothesis is true, then this would 
suggest that residues that could be involved in patch 2 interactions of DJ-1Δ15 




formation of a hexamer is less important to the function of DJ-1 (or DJ-1Δ15) 
compared to that of PH1704. 
 
2.5 Conclusion 
In summary, our data suggest that DJ-1Δ15 can potentially form high order 
oligomeric species. Specifically, we showed via computational analysis that DJ-
1Δ15 potentially forms a closed hexamer by forming a new interface (patch 1’). In 
contrast, full-length DJ-1 cannot adopt a hexameric structure due to steric 
conflicts involving helix 8. Formation of the DJ-1Δ15 hexamer may be necessary 
for the protease activity of this variant because the new interfaces formed upon 
assembly of a trimer of dimers may lead to the formation of a catalytic triad. 
Studies of DJ-1Δ15 in solution showed that DJ-1Δ15 forms oligomeric species 
larger than a homodimer in a concentration-dependent manner. Further efforts 
are underway to determine whether the formation of these high molecular weight 


















Figure 2.2 Overlaid structures of PH1704 half-hexamer (1G2I, green) and WT DJ-1  
(1P5F, cyan) or DJ-1Δ15.  
 
(A) WT DJ-1 does not form a hexamer because helix 8 causes steric hindrance at the patch 1’ 
interface. Helix 8, C106, H126, and E84’ of DJ-1 are shown. (B) DJ-1Δ15 overlays well with PH1704 






Figure 2.3 Structural model showing a closed hexamer that could be formed by DJ 1Δ15.  
DJ-1Δ15 can form a closed  hexamer as a result of removal of the 15 C-terminal  residues and 
a 90° rotation between two subunits, allowing for conversion of the patch 1 interface to the 
patch 1’ interface. This conformational change is necessary for patch 2 interactions leading to 
the assembly of a hexamer (trimer of dimers) with a closed structure. (Structural model 








Figure 2.4 Structural model showing an open hexamer that could be formed by DJ1Δ15.  
DJ-1Δ15 is expected to form an open hexamer upon self-assembly in the absence of a 90°rotation 
between two subunits, so that the patch 1 interface is not converted to the patch 1’ interface.  (Structural 










 Figure 2.5 Potential DJ-1Δ15 catalytic triad. 
(A) Formation of the DJ-1Δ15 hexamer brings a glutamate residue 84 (E84’) from one subunit to within 9.5 Å of 
cysteine 106 (C106) and 5.5 Å of histidine (H126), and this positioning of the three residues may result in the 
assembly of a catalytic triad. (B) PH1704 forms a catalytic triad with E74’ from one subunit placed within 7.3 Å of C100 





















  pT7-7  
Figure 2.6 SDS-PAGE gel showing that DJ-1Δ15 has a lower molecular weight compared to WT DJ-1.  
The following proteins (3 μg) were analyzed: WT DJ-1 purified from E. coli expressing a pGEX-6p-1 construct; 
DJ-1Δ15 purified from E. coli expressing a pGEX-6p-1 construct; and DJ-1Δ15 purified from E. coli 



















Figure 2.7 Western blot of SDS-PAGE gel showing evidence of DJ-1Δ15 oligomerization.  
WT DJ-1 and DJ-1Δ15 were ultracentrifuged at 100,000 rpm (300,000 xg) at 4ºC for 30 min. The supernatant 
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pGEX-6p-1 
Figure 2.8 Native PAGE gel showing that high order oligomer are only minor in two different preparation 














Higher molecular species   
A B 
Figure 2.9 Analysis of DJ-1Δ15 purified as an untagged protein via AUC. 
(A) Sedimentation-velocity data showing total protein signal (interference fringes) versus radial distance in an 
ultracentrifugation cell with DJ-1Δ15 at different sedimentation times. (B) Plot showing the distribution of species 
with different sedimentation coefficients (S) at three different concentrations of protein (0.75 mg/ml, 0.38 mg/ml 















Higher molecular species   
Figure 2.10 AUC analysis of DJ-1Δ15 purified as a GST-tagged protein and subsequently cleaved for tag 
removal). 
  
(A) Sedimentation-velocity data showing total protein signal (interference fringes) versus radial distance in an 
ultracentrifugation cell with DJ-1Δ15 at different sedimentation times. (B) Plot showing the distribution of species 





CHAPTER 3: DJ-1 INTERACTS WITH E.COLI F1 ATP SYNTHASE 
3.1 Introduction 
DJ-1 has been implicated in many cellular protective functions including a 
peroxiredoxin function and the ability to act as molecular chaperone [108, 141, 
142, 190], but the exact mechanism for its neuroprotective function is unknown. 
Molecular chaperones are large a class of proteins that suppress protein 
misfolding, aggregation and aid in refolding denatured proteins [191, 192]. 
Included in this large class of proteins are multiple heat shock proteins (Hsps) 
[191, 192], many of which function in an ATP-dependent manner [191, 192]. 
Another class of proteins, peroxiredoxin (Prxs), functions as both molecular 
chaperones and peroxidases [193]. A number of Prxs have been shown to form 
high molecular weight structures, up to five dimers linked by hydrophobic 
interactions [194].  The dual functions of Prxs are modulated by oxidative stress, 
which can induce dramatic changes in quaternary structure [195]. 
DJ-1 has been described as an atypical Prx that scavenges hydrogen peroxide 
(H2O2) via oxidation of Cys106 [190]. The reaction of cysteinyl thiolates with H2O2 
yields multiple oxidation forms: sulfenic acid (–SOH), sulfinic acid (–SO2H), 




and disulfide S-oxides [196-199]. Hyperoxidation of Prxs to the sulfinic acid form 
results in inactivation. In some cases this inactivation can be reversed by 
sulfiredoxin, a protein that provides an ATP molecule which is a target for 
nucleophilic attack by the cysteine sulfinic acid, resulting in the formation of 
sulfinic acid phosphoryl ester intermediate. In turn, reaction of this intermediate 
with a sulfiredoxin cysteine residue (or a small-molecule reductant) releases a 
phosphate and results in the formation of a thiosulfinate intermediate, which can 
be reduced to regenerate the sulfenic acid form of the Prx [200] .   
Analysis of the DJ-1 crystal structure revealed a previously undescribed potential 
ATP binding site that included two arginine residues, Arg 28 and Arg 48, near the 
oxidizable Cys106 residue.  These residues could potentially serve as binding 
sites for the beta and gamma phosphates of ATP. A former graduate student in 
the lab, Kristen Lesniak, showed that a nonhydrolyzable analog of ATP (ATPγS) 
stabilized DJ-1 in a pulse-proteolysis assay (unpublished data). In addition, a 
preparation of recombinant human wild-type DJ-1 purified from E. coli was found 
to bind and hydrolyze ATP and GTP, but not CTP, TTP, or ADP.  
In this study we carried out a series of biochemical experiments to determine the 
source of the ATPase activity in our DJ-1 preparations. Our results show that DJ-
1 interacts with E.coli F1 ATP synthase and this interaction may be relevant to 
DJ-1 chaperone activity. Our data also suggest that the reduced form of DJ-1 
preferentially interacts with F1 ATPase. These findings provide new insights into 
the biochemical mechanism by which DJ-1 preserves mitochondrial function in 




a protein complex that is structurally and functionally well conserved between E. 
coli and eukaryotic mitochondria.  
 
3.2 Materials and Methods 
   3.2.1 Materials  
The bicinchoninic acid (BCA) protein assay kit was obtained from Pierce 
Biotechnology (Rockford, IL). The ECF substrate was purchased from GE 
Healthcare (Piscataway, NJ).  Coomassie Brilliant Blue R250 and SDS were 
obtained from Amresco (Solon, OH). All other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO).  
3.2.2 Antibodies 
The following antibodies were used in these studies: mouse anti human DJ-1 
(3E8) (Enzo Life Sciences, Farmingdale, NY), secondary anti mouse IgG 
conjugated with alkaline phosphatase (Promega, Madison, WI, USA, Cat. # 
S3721), secondary anti rabbit IgG conjugated with alkaline phosphatase 
(Promega, Madison, WI, USA, Cat # S3731). Anti ATP beta subunit (ATPB) 
(7E3F2) (Abcam, Cambridge, MA, USA). 
3.2.3 DJ-1 protein purification 
DJ-1 was purified as explained earlier in Chapter 2.  
3.2.4 A continuous fluorimetric assay to measure ATPase activity 
ATPase activity was monitored via a continuous fluorimetric assay. In the 
presence of phosphate, nucleoside phosphorylase (PNP) will convert 7-methyl-




non-fluorescent molecule, thus decreasing the fluorescence [201]. WT DJ-1 was 
dialyzed against 2 L of 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, and 1 mM MgCl2. 
Protein concentration was determined using the BCA assay, and 15 μg of DJ-1 
was mixed with 7-methyl-guanosine (M7Guo) (4 mM), 0.1 units of PNP, 1 mM 
MgCl2, and 1 mM ATP in a 1 mL quartz spectrometer cuvette (Sigma Aldrich, St. 
Louis MO). The decrease in fluorescence was observed at 410 nm (the excitation 
wavelength was 300 nm) using a FluoroMax 3 fluorescence spectrophotometer 
(HORIBA Jobin Yvon, Edison, NJ).  
3.2.5 Filtration of DJ-1 samples 
WT DJ-1 was dialyzed against 2 L of 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, and 
1 mM MgCl2. The protein was later applied to a 100 kDa spin filter (Millipore 
Billerica, MA). The filter was spun at 2,000 xg for 4 min at 4 ºC. The filtrate was 
recovered, and protein concentration was determined using the BCA kit before 
analysis of ATPase activity.   
3.2.6 Size Exclusion Chromatography (SEC)  
WT DJ-1  (~1 mg/mL final concentration) was dialyzed against 50 mM Tris-HCl, 
pH 7.5, 50 mM NaCl, and 1 mM MgCl2, and an aliquot (200 μg) was applied to a 
Superdex 200 10/30 size exclusion chromatography (SEC) column (GE 
Healthcare). The protein was eluted with the same buffer used for dialysis at a 
flow rate of 0.5 mL/min, monitoring absorbance at 280 nm. Apparent molecular 
weights of eluted proteins were determined using a calibration curve established 
with the following standards: blue dextran (>600 kDa), bovine serum albumin 





WT DJ-1 was dialyzed in 2 L of a buffer consisting of 50 mM Tris-HCl, pH 7.5, 50 
mM NaCl, and 1 mM MgCl2 for 16 h at 4ºC. The protein was then ultracentrifuged 
at 47,000 rpm (100,000 xg) at 4ºC for 2 h using a Beckman ultracentrifuge (Dr. 
Chris Hrycyna, Purdue University, Chemistry). The supernatant was removed, 
and the pellet was resuspended in dialysis buffer.  
3.2.8 Sucrose gradient centrifugation 
A series of sucrose solutions (5%-50%, w/v) was prepared in 50 mM Tris-HCl, 
pH 7.5, 50 mM NaCl, 1 mM MgCl2. An aliquot of each solution (2 mL) was 
carefully layered into an ultracentrifuge tube (16x89mm, Beckman), starting with 
the 50% solution at the bottom. To separate high-MW species in the DJ-1 
preparation from the predominant homodimer, the protein sample was loaded on 
the 5% sucrose solution (top-most layer of the gradient), and ultracentrifugation 
was carried out at 40,000 rpm (274,000 xg) for 18 h at 4 ºC. Fractions of about 
500 μL were collected from the bottom of the tube by puncturing the tube bottom. 
The samples were analyzed via Western blotting using antibodies specific for DJ-
1 and ATPB. 
3.2.9 Western blotting  
After measuring the concentration of protein solutions using the BCA Protein 
Assay Kit (Pierce Biotechnology, Rockford, IL, USA), equal amounts of protein 
were separated via SDS–PAGE on a 4-20% or 12% (w/v) polyacrylamide gels. 
Due to the low amount of protein in the sucrose gradient fractions, the protein 




(12 μL) of each fraction was loaded on the gel. The proteins were transferred to a 
0.2 μm polyvinylidene fluoride (PVDF) membrane, which was then probed with a 
primary antibody specific for DJ-1 (1:4000), oxidized DJ-1 (1:5000), GST 
(1:5000), or ATPB (1:5000). The membrane was treated with a secondary anti-
mouse or anti-rabbit alkaline phosphatase-conjugated antibody (1:6000) or using 
a secondary fluorescence goat anti-rabbit/Alexa Fluor 488 (Life technologies, 
Carlsbad CA) and goat anti-mouse Alexa Fluor 594 (Life technologies, Carlsbad 
CA). Images were obtained and analyzed using a Typhoon imaging system (GE 
Health Sciences, Piscataway, NJ, USA).  
3.2.10 Transmission Electron Microscopy (TEM) 
Gradient fractions (10 μL) were deposited on glow–discharged carbon-coated 
copper grids (FCF400-Cu), and the grids were rinsed with three drops of 50 mM 
Tris-HCl, pH 7.5, 50 mM NaCl, and 1 mM MgCl2. The grids were then negatively 
stained with 1% (w/v) uranyl-acetate. Images were generated using an electron 
microscope (CM200 transmission electron microscope (TEM), (Phillips, 
Amsterdam, Netherlands) operated at 200 kV, in collaboration with Dr. Lia 
Stanciu (Department of Materials Engineering, Purdue University). 
3.2.11 Mass Spectrometry  
Samples obtained from the 50% sucrose gradient fraction were first denatured in 
a buffer consisting of 8 M urea, 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, and 1 mM 
MgCl2. To reduce disulfide bonds, DTT was added to a final concentration of 10 
mM, and the samples were incubated at 37 ºC for 1 h. Iodoacetamide was added 




h to alkylate the reduced cysteine residues. After dilution with a five-fold excess 
of buffer, the samples were incubated with trypsin (10 μg per mg of protein) for 
12-16 h at 37 ºC. The samples were then desalted using a C-18 capillary column 
packed with 5 μm C18 Magic bead resin (Michrom; 75 μm i.d. and 12 cm of bed 
length)  and analyzed via mass spectrometry (UPLC: EASY-nLC 1000 Liquid 
Chromatograph (Thermo Scientific). Mass Spec: Thermo Fisher LTQ-Orbitrap 
Velos) in collaboration with Lingfei Zeng and Dr. Andy Tao (Department of 
Biochemistry, Purdue University). 
3.2.12 Database search 
The LTQ-Orbitrap raw files were searched directly against the human, E. coli or 
S. japonicum database using SEQUEST on Proteome Discoverer (Version 1.4, 
Thermo Fisher). Proteome Discoverer created DTA files from raw data files with 
minimum ion threshold 15 and absolute intensity threshold 50. Peptide precursor 
mass tolerance was set to 10 ppm, and MS/MS tolerance was set to 0.6 Da. 
Search criteria included a static modification of cysteine residues of +57.0214 Da 
and a variable modification of +15.9949 Da to include potential oxidation of 
methionine. Searches were performed with full tryptic digestion and allowed a 
maximum of two missed cleavages on the peptides analyzed from the sequence 
database. False discovery rates (FDR) were set to 1% for each analysis. Two 






3.3 Results  
3.3.1 A preparation of recombinant WT DJ-1 loses ATPase activity 
upon filtration.   
To preserve our DJ-1 preparation, we filtered the protein through a filter with a 
molecular weight cutoff of 100 kDa to remove any microbial contaminants. We 
tested the ATPase activity of our DJ-1 preparation before and after filtration using 
a continuous fluorescence assay (PNP). Surprisingly, our results showed that the 
ATPase activity of the DJ-1 preparation was absent in the filtrate (Fig 3.1). These 
data suggested that the ATPase activity was associated with either a high 
molecular weight form of DJ-1 or another high molecular weight protein in the DJ-
1 preparation.  
To further confirm the filtration results, we used a size exclusion chromatography 
(SEC) approach. The homodimer purified using a superdex-200 column was 
analyzed for ATPase activity using the PNP assay with or without ATP. The 
results showed that homodimer ATPase activity, and doubling the amount of the 
DJ-1 homodimer used in the assay did not change the results (Fig 3.2). 
Taken together, these results suggest that (i) the ATPase activity was associated 
with either a high molecular weight form of DJ-1 or another high molecular weight 
protein in the DJ-1 preparation, and (ii) DJ-1 homodimer, isolated via SEC did not 




3.3.2 A preparation of recombinant WT DJ-1 contains DJ-1-
immunoreactive high molecular weight (high-MW) species.  
Our next goal was to determine the molecular basis for the ATPase activity in our 
DJ-1 preparations. We hypothesized that DJ-1 forms a high molecular weight 
complex under oxidizing conditions, similar to Prx [195]. In addition, we 
hypothesized that the high MW form of DJ-1 has ATPase activity, based on our 
observation that the ATPase activity in our DJ-1 preparations could be removed 
by filtration. To address this hypothesis, we first examined whether a portion of 
the DJ-1 in our recombinant protein preparations existed as a high-MW complex. 
We separated high-MW species using two well-established separation methods, 
ultracentrifugation and sucrose gradient ultracentrifugation.   
As an initial approach to separate WT DJ-1 high-MW species, the dialyzed 
protein was ultra-centrifuged. The dimeric DJ-1 fraction (supernatant) was 
removed by careful pipetting, while the high-MW species fraction (pellet) at the 
bottom of the tube was resuspended in buffer. The supernatant and pellet 
fractions and an aliquot of WT DJ-1 with mixed species (not ultracentrifuged 
‘uncentr’) were fractionated on an SDS PAGE gel and analyzed via Western 
blotting with an antibody specific for DJ-1. Our results showed evidence of higher 
amounts of DJ-1-positive high molecular weight bands in the pellet fraction 
compared to the supernatant (S/N) fraction. In addition, there was a decreased 
intensity of monomeric DJ-1 in the pellet fraction (Fig 3.3).   
As an alternative method, we analyzed our DJ-1 samples via sucrose gradient 




(5%). After centrifugation, three fractions from each of several zones of the 
gradient (corresponding to sucrose percentages of 20%, 30%, and 50%, v/v) 
were collected, and an aliquot of each fraction (500 μL) was analyzed via 
Western blotting. Our results showed higher levels of high-MW species in the 
50% sucrose fraction compared to the other fractions (Fig 3.4). Taken together, 
our results suggest that our DJ-1 preparation contains DJ-1-immunoreactive 
high-MW.   
3.3.3 The high MW fraction from our WT DJ-1 preparation contains 
ATPase activity.  
Our next goal was to examine whether the ATPase activity observed in our 
preparations of human WT DJ-1 was associated with the high-MW species 
described in the previous section. Based on our earlier observation that DJ-1 
samples lost the ability to hydrolyze ATP upon filtration, we hypothesized that the 
ATPase activity would track with fractions enriched with high-MW species. To 
address this hypothesis, high-MW species were separated using the two 
ultracentrifugation methods described above.  
The fractions obtained via ultracentrifugation (non-sucrose gradient) were 
analyzed for the release of inorganic phosphate in the absence or presence of 
ATP using a continuous fluorescence assay (PNP). The results showed that the 
pellet fraction had a higher ATPase activity, whereas the S/N fraction showed no 
ATPase activity (Fig 3.5).  
Data from the sucrose gradient ultracentrifugation analysis revealed that fractions 




ATPase activity, whereas fractions with lower percentages of sucrose showed 
markedly less ATPase activity (Fig 3.6).    
Taken together, these results suggest that a high-MW, DJ-1-immunoreactive 
species in our preparations of recombinant human WT DJ-1 purified from E.coli 
has ATPase activity.    
3.3.4 Sucrose fractions with ATPase activity contain ring-like 
structures.  
Previous studies have reported that DJ-1 acts a molecular chaperone [141, 142], 
and a number of molecular chaperones have been shown to form high molecular 
species [194]. The next set of experiments was designed to determine the 
structural properties of high-MW weight protein species in sucrose fractions with 
ATPase activity. As one possibility, we hypothesized that DJ-1 might undergo 
self-assembly to form a high-MW chaperone, perhaps under oxidizing conditions 
as described for various peroxiredoxins [195], and such a DJ-1 high-MW 
chaperone might have ATPase activity. Alternatively, we considered the 
possibility that DJ-1 might interact with another high MW protein with ATPase 
activity. To address these hypotheses, we analyzed the fractions obtained by 
sucrose gradient ultracentrifugation via electron microscopy (EM). Our results 
showed that fractions with the highest percentage of sucrose (40-45%), which 
also showed high ATPase activity (see above), consisted of ring-like structures 
with a diameter of approximately 20-50 nm (Fig 3.7). In contrast, these structures 
were absent from fractions with lower percentages of sucrose and negligible 




supernatant obtained via ultracentrifugation of a DJ-1 preparation in the absence 
of sucrose (this supernatant fraction consisted mainly of DJ-1 homodimer and did 
not show any ATPase activity). Moreover, a sample of purified GST lacked the 
ring-like structures (data not shown).  
From these findings, we infer that high-MW species present in fractions 
with ATPase activity consist of ring-like structures, whereas these structures are 
absent from fractions containing homodimeric DJ-1, which also lack ATPase 
activity. Our data show that the ATPase activity present in the high-MW fraction 
of our DJ-1 preparations tracks with ring-like structures observable by EM, 
raising the possibility that the ATPase activity could be associated with these 
structures. 
3.3.5 Analysis of the high MW fraction of our DJ-1 preparation by 
mass spectrometry revealed the presence of E. coli F1 ATP 
synthase subunits. 
As mentioned above, we considered two hypotheses to account for the presence 
of DJ-1 protein and ATPase activity in a high MW fraction obtained from our DJ-1 
preparation by sucrose gradient sedimentation: first, that DJ-1 might oligomerize 
to form a high MW chaperone with ATPase activity; and second, that DJ-1 might 
interact with another high-MW protein with ATPase activity. Two key findings led 
us to favor the second hypothesis: (i) we were unable to generate a high-MW 
form of DJ-1 with ATPase activity upon incubation under oxidizing or reducing 
conditions; and (ii) a preparation of the C106A mutant of DJ-1 also had ATPase 




role in the conversion of DJ-1 to a high-MW form by analogy with the self-
assembly mechanism of redox-sensitive peroxiredoxins [195].  
To determine the protein composition of the high-MW (high sucrose) fraction 
from our DJ-1 preparation, a sample of the high MW fraction was subjected to 
tryptic digestion and analyzed via mass spectrometry (MS) in collaboration with 
Dr. Andy Tao (Purdue University).  A sample of recombinant (purified) GST was 
also analyzed via MS as a control. The peptide masses obtained from the MS 
analysis were searched against three databases: human, E.coli and Schistosoma 
japonicum (the species from which is derived the GST tag). The MS data 
revealed the presence of DJ-1 in the human database search, with a score of 
93.41.  The E.coli database search revealed the presence of E. coli F1 ATP 
synthase subunits: alpha α, beta β, delta ?, and gamma γ. Highest scores were 
obtained for the β and α subunits (Table 3.1), which are known to assemble into 
ring-like structures. Other E. coli proteins revealed by the MS analysis included 
F0 subunit b, in addition to a number of other ATP-binding proteins (Table 3.1). 
The Schistosoma japonicium database search revealed the presence of GST 
with a score of 210.52. Since we did not observe any ATPase activity with GST 
(Fig 3.8), we predicted that we would not detect ATPase subunits in the GST 
mass spec data. This was confirmed. These results suggest that the proteins in 
the high-MW fraction of our DJ-1 preparation include DJ-1, E.coli F0 and F1 
ATPase subunits, other ATP-binding proteins, and GST. Therefore, we 
concluded that (i) DJ-1 might be interacting with other E.coli proteins in our 




potentially exists as ring-like structures and (ii) purified GST protein lacked the 
ATPase activity.   
3.3.6 Analysis of the high MW fraction of our DJ-1 preparation by Western 
blotting revealed the presence of the beta subunit of E. coli F1 ATP synthase 
(ATPB).  
The MS data presented above suggested that E. coli ATP synthase was present 
in the high MW fraction of our DJ-1 preparation. To obtain additional evidence in 
support of this idea, we examined the fractions obtained by sucrose-gradient 
sedimentation of our DJ-1 preparation via Western blotting. The primary 
antibodies used in this analysis were specific for human DJ-1 or the E. coli F1 
ATP synthase beta subunit (ATPB). The results showed that ATPB (50 kDa) was 
present primarily in the 15% sucrose gradient fractions, but also in the 50% 
sucrose fractions and to a lesser extent in the 20% and 30% sucrose fractions 
(Fig 3.9). These results confirm that ATPB is indeed present in the high MW 
fraction of our DJ-1 preparation, mostly in an unassembled state detected in the 
15% sucrose fraction but also in a higher-MW state (presumably as part of 
assembled F1 ATP synthase) detected in the 50% sucrose fraction [202]. 
3.3.7 The ATPase activity in the high-MW fraction of our DJ-1 
preparation is inhibited by sodium azide and piceatannol.  
Sodium azide and piceatannol are two known classical F1 ATPase inhibitors 
[203]. To address whether the ATPase activity in our DJ-1 preparation could be 
associated with assembled F1 ATPase, we tested whether the ATPase activity 




recombinant DJ-1 was analyzed for ATPase activity with or without sodium azide 
(1 mM and 5 mM) in the PNP assay, or in the absence or presence of 
piceatannol in the MG assay. The results showed that sodium azide and 
piceatannol both abolished the ATPase activity (Fig.3.10 and Fig 3.11). These 
results suggest that the ATPase activity in our DJ-1 preparation could originate 
from assembled F1 ATPase. 
3.3.8 Evidence of a potential interaction between DJ-1 and E coli F1 
ATP synthase. 
The next sets of experiments were designed to test the hypothesis that DJ-1 
interacts with F1 ATP synthase. To address this hypothesis, the supernatant 
fraction of our DJ-1 preparation (obtained after ultracentrifugation in the absence 
of sucrose to remove the high-MW species) was incubated with or without 
purified bacterial F1 ATPase (obtained from Dr. Ahmad Zulfiqar, Kirksville College 
of Osteopathic Medicine, MO). The incubation mix was fractionated by sucrose 
gradient sedimentation. The sucrose gradient fractions were analyzed via 
Western blotting using primary antibodies specific for DJ-1 and the E. coli F1 ATP 
synthase beta subunit. The results showed that DJ-1 sediments to fractions with 
a higher percentage of sucrose after incubation with F1 ATPase, as evidenced by 
the presence of DJ-1 immunoreactive bands in lanes corresponding to the 30-
50 % sucrose fractions (Fig 3.12).  In contrast, DJ-1 was not detected in the 
same sucrose fractions obtained upon sedimentation of a sample of DJ-1 
incubated without F1 ATP synthase (Fig 3.13).  As expected, most of the E. coli 




inferred from the sedimentation of the E. coli F1 ATP synthase beta subunit. 
Therefore, we conclude that homodimeric DJ-1 present in the supernatant 
fraction might interact with E. coli F1 ATP synthase to form a high-MW complex. 
3.3.9 DJ-1 in the high MW fraction has a low level of C106 
oxidation. 
Based on the results above, we investigated whether the oxidation of DJ-1 
modulates the protein’s interaction with E coli F1 ATP synthase. To address this 
hypothesis, DJ-1 (supernatant fraction) was incubated with E coli F1 ATP 
synthase at room temperature, and the mixture was analyzed via sucrose 
gradient sedimentation. Sucrose fractions were analyzed via Western blotting 
using antibodies specific for the oxidized form of DJ-1 or total DJ-1. Our results 
showed that DJ-1 (detected with a total DJ-1 antibody) incubated with E coli F1 
ATP synthase sediments to higher sucrose fraction (Fig 3.14), while  oxidized 
DJ-1 (detected with an antibody specific for oxidized DJ-1) does not sediment to 
higher fractions (Fig 3.15). These findings suggest that the oxidation state of DJ-
1 modulates its interaction with F1 ATPase, and that reduced DJ-1 more readily 
interacts with E coli F1 ATPase. 
 
3.4 Discussion 
DJ-1 has been shown to be involved in many neuroprotective functions, but its 
biochemical function still remains to be elucidated.  In this chapter we described 




interaction with E.coli F1 ATPase, a protein complex that is structurally and 
functionally well conserved with F1 ATPase with eukaryotic mitochondria. 
3.4.1 A High MW fraction of our DJ-1 preparation is DJ-1-
immunoreactive, has ATPase activity and contains ring-like 
structures  
Our results revealed that ATPase activity in our DJ-1 preparation was abolished 
by filtration. Sucrose gradient sedimentation and Western blot analysis showed 
the presence of high-MW species immunoreactive with DJ-1 antibody in our 
preparations of recombinant, human WT DJ-1. In addition, we found that the 
high-MW fraction had ATPase activity and contained ring-like structures that 
were visible by EM. Previous studies revealed that DJ-1 functions as a molecular 
chaperone [141, 142]. In addition the formation of  high molecular weight 
structures  by Prxs is  modulated by oxidative stress, which can induce dramatic 
changes in quaternary structure [194] [195].  Accordingly, we inferred as one 
possibility that DJ-1 might form a high-MW species that functions as an ATP-
dependent molecular chaperone. However, two observations contradicted this 
hypothesis: homodimeric DJ-1 fractions without the high-MW species (after 
separation via sucrose gradient ultra-centrifugation, SEC, and filtration) did not 
show any ATPase activity or form ring-like structures, even after incubation,  and 
the C106A mutation had no effect on ATPase activity (data not shown). For this 
reason, we turned our attention to analyzing the interaction of DJ-1 with E. coli 




3.4.2 DJ-1 positive Interacts with E.coli F1 ATP synthase to form 
high-MW species. 
MS analysis of the high-MW fraction isolated by sucrose gradient centrifugation 
revealed the presence of E. coli F1 ATP synthase subunits, which are known to 
assemble into ring-like structures [204].  A previous proteomics study revealed 
that DJ-1 interacts with the α- and β-subunits of F1 ATP synthase in a rat 
mesencephalic cell line [205]. The fact that the high MW fraction hydrolyzes ATP 
and GTP, but not CTP, TTP, or ADP, is consistent with the idea that the ATPase 
activity in our DJ-1 preparation originates from assembled F1 ATP synthase 
[206]. Moreover, the high-MW fraction exhibited ATPase activity that was 
inhibited by sodium azide and piceatannol, two inhibitors of F1 ATP synthase. In 
addition, we found that homodimeric DJ-1 sedimented to fractions with a higher 
percentage of sucrose after incubation in the presence versus the absence of 
E.coli F1 ATP synthase.  Collectively, these results imply that DJ-1 interacts with 
E. coli F1 ATP synthase. Importantly, this proposed interaction is specific to DJ-1 
because a sample of GST purified using the same bacterial expression system 
did not show any ATPase activity. Our findings suggest that DJ-1 may interact 
with F1 ATP synthase because this interaction may be a key component of the 
DJ-1 chaperone function. MS results suggested that recombinant human DJ-1 
might interact with other bacterial proteins, including E. coli F0 ATP synthase.  
Although our studies were carried out with E.coli F1 ATP synthase, we 
would predict that DJ-1 might interact in a similar way with F1 ATP synthase from 




high degree of structural and functional similarity [207]. DJ-1 has been described 
as an atypical Prx that scavenges hydrogen peroxide (H2O2) via oxidation of 
Cys106 [190]. The interaction between DJ-1 and ATP synthase (if validated) 
would represent a new development in our understanding of how the protein 
modulates mitochondrial function. 
3.4.3 Unoxidized DJ-1 is the form of the protein that apparently 
interacts with E.coli F1 ATP synthase. 
A previous study showed that under conditions of oxidative stress, cysteine 106 
(Cys 106) of DJ-1 becomes oxidized to the sulfinic and sulfonic acids (Cys-SO2H 
and Cys-SO3H, respectively) [208]. We found that oxidized DJ-1 does not readily 
interact with F1 ATP synthase, suggesting that the interaction of DJ-1 with E.coli 
F1 ATPase is modulated by C106 oxidation. This observation suggests (as one 
possibility) that DJ-1 forms a disulfide bond with one of the F1 ATP synthase 
subunits, a mechanism that has precedence in disulfide bond formation between 
DJ-1 and Ask1 kinase [121] 
 
3.5 Conclusion 
The data outlined in this chapter suggest that recombinant human DJ-1 (and in 
particular the reduced form of the protein) interacts with E. coli F1 ATP synthase, 
thereby enhancing ATP synthase function (e.g. perhaps via a mechanism 
involving DJ-1 chaperone activity). We expect that a similar interaction is likely to 




interaction could play an important role in alleviating mitochondrial dysfunction 


























Figure 3.1-A ATPase activity associated with purified DJ-1 is eliminated upon filtration.   
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5 . A portion 
of the protein was filtered through a 100 kDa filter. Equal amounts (15 μg)  of the filtered and 
unfiltered proteins were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic 
conversion of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a 
continuous fluorimetric assay in the absence or presence of 1 mM ATP.  Excitation, 300 nm; 
emission, 410 nm. B. Table showing the slope and R
2


































Figure 3.1-C. ATPase activity associated with purified DJ-1 is absent in the filtrate.  





Figure 3.2 ATPase activity associated with purified DJ-1 is absent in the homodimer fraction.   
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. The protein was 
loaded onto a Superdex column, S200 and elution peaks were collected by monitoring the ultraviolet 
absorbance detector. Equal amounts of protein (15 μg) from the S200 column were used in the  PNP 
assay. ATP hydrolysis was monitored by the enzymatic conversion of 7-methylguanosine to 7-
methylguanine, which has a lower quantum yield, via a continuous fluorimetric assay in the absence or 
presence of 1 mM ATP.  Excitation, 300 nm; emission, 410 nm.  B. Absolute slope values from panel A 
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Figure 3.3 WT DJ-1 forms high molecular weight species.  
WT DJ-1 was ultracentrifuged at 47,000 rpm (100,000 xg) at 4ºC for 2 h. The supernatant (S/N) 
was removed, and the pellet was resuspended in buffer. Equal amounts of protein (1 μg) 
(including the uncentrifuged protein, ‘Uncentr’) were then analyzed via Western blotting using a 
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Figure 3.4  WT DJ-1 forms high molecular weight species.   
DJ-1 high-MW species were separated via ultracentrifugation through a sucrose gradient (20-50% 
w/v) at 40,000 rpm (274,000 x g) for 18 h at 4 ºC. Gradient fractions were collected and analyzed 
by SDS-PAGE on a 4-20% gradient gel. The proteins were transferred to a PVDF membrane and 
probed with an antibody specific for DJ-1.  Asterisk indicates a band that could correspond to 







Figure 3.5 DJ-1 associated high molecular weight fractions have ATPase activity.   
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. The protein was 
ultracentrifuged at 47,000 rpm (100,000 xg) at 4ºC for 2 h. The supernatant (S/N) was removed, and the 
pellet was resuspended in buffer. Equal amounts of protein (15 μg) (including the uncentrifuged protein, 
‘Uncentr’) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic conversion of 7-
methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous fluorimetric 
assay in the absence or presence of 1 mM ATP.  Excitation, 300 nm; emission, 410 nm. B. Absolute slope 








Figure 3.6 DJ-1 fractions with a high sucrose percentage had a high ATPase activity.  
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. The protein sample was 
loaded on a 5% sucrose (top most sucrose percentage layer), and ultracentrifugation was carried out at 40,000 
rpm (274,000 xg) for 18 h at 4 ºC. Fractions of about 500 μL each were collected from the bottom of the tube. 
Equal amounts of protein (15 μg) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic 
conversion of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous 
fluorimetric assay in the absence or presence of 1 mM ATP.  Excitation, 300 nm; emission, 410 nm. B. Absolute 
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Figure 3.7 WT DJ-1 oligomer consists of ring-like structures.  
 Fractions collected from a sucrose gradient (Figure 3.6) (10 μL) were deposited on carbon-coated 
copper grids and negatively stained using 2 % uranyl-acetate. The images were taken using an 
electron microscope. Collaboration with Dr. Stanciu’s lab. Ring-like structures (arrow) were only 

























Figure 3.8 GST lacks ATPase activity.   
A. GST was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. Equal amounts of 
protein (15 μg) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic conversion 
of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous fluorimetric 
assay in the absence or presence of 1 mM ATP.  Excitation, 300 nm; emission, 410 nm.  B. Absolute 






Figure 3.9 WT DJ-1 sucrose fractions are immunoreactive for the E.coli ATPB subunit.   
 WT DJ-1 was dialyzed and separated via ultracentrifugation through a sucrose gradient (5-50% w/v) 
at 40,000 rpm (274,000 x g) for 18 h at 4 ºC. Gradient fractions were collected and analyzed by SDS-
PAGE on a 4-20% gradient gel. The proteins were transferred to a PVDF membrane and probed with 
an antibody specific for DJ-1 (A) and E.coli ATPase beta subunit (ATPB) (B).  N=2 
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Figure 3.10 ATPase activity associated with purified DJ-1 is inhibited by sodium azide.   
A. WT DJ-1 was dialyzed against 50 mM Tris-HCl, 50 mM NaCl, 1 mM MgCl2, pH 7.5. Equal amounts of 
protein (15 μg) were used in the PNP assay. ATP hydrolysis was monitored by the enzymatic conversion 
of 7-methylguanosine to 7-methylguanine, which has a lower quantum yield, via a continuous fluorimetric 
assay in the absence or presence of 1 mM ATP with 1 mM and 5 mM sodium azide.  Excitation, 300 nm; 










Figure 3.11 ATPase activity associated with purified DJ-1 is inhibited by piceatannol. WT DJ-1 protein (1 
μg) was incubated in the presence of 1 mM ATP, with or without 20 μM piceatannol, for 2 h at 37 ºC. Hydrolysis 
of ATP was monitored using a malachite green assay designed to monitor the formation of a green 
molybdophosphoric acid complex, which reports on the free organic phosphate concentration. The values were 















Figure 3.12 WT DJ-1 sediments to the 30-50% sucrose fractions after incubation with F1 ATPase.  
A. WT DJ-1 (supernatant) was incubated with E.coli  F1 ATPase at room temperature for 1 h. The complex formed 
was separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000 x g) for 16 h at 
4 ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel. The proteins were 
transferred to a PVDF membrane and probed with an antibody specific for DJ-1 and E.coli ATPase beta subunit 
















Figure 3.13 WT DJ-1 sediments to the 15% sucrose fractions without incubation with F1 ATPase. 
 
A. WT DJ-1 (supernatant) was incubated without E.coli F1 ATPase at room temperature for 1 h. The sample 
was separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000 x g) for 
16 h at 4 ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel. The 
proteins were transferred to a PVDF membrane and probed with an antibody specific for DJ-1.  B. 
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Figure 3.14 Unoxidized DJ-1 sediments with F1 ATP synthase to higher sucrose fractions.  
A. WT DJ-1 (supernatant) was incubated without E.coli  F1 ATP synthase  at room temperature for 1 h. The 
sample was separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000 
x g) for 16 h at 4 ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel. 
The proteins were transferred to a PVDF membrane and probed with an antibody specific for DJ-1 
(unoxidized). B. Quantification of the relative DJ-1 band intensities in different percentages of sucrose using 
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Figure 3.15 Oxidized DJ-1 does not sediment with F1 ATPase to higher sucrose fractions.  
A. WT DJ-1 supernatant was incubated without E. coli  F1 ATPase at room temperature for 1 h. The sample was 
separated via ultracentrifugation using a sucrose gradient (5%-50% w/v) at 40,000 rpm (274,000 x g) for 18 h at 4 
ºC. Gradient fractions were collected and analyzed by SDS-PAGE on a 4-20% gradient gel. The proteins were 
transferred to a PVDF membrane and probed with an antibody specific for oxidized DJ-1.  B. Quantification of the 











Magnesium-transporting ATPase, P-type 1 360.80 47.55 1 46 
ATP synthase subunit alpha  327.88 74.07 1 34 
ATP synthase subunit beta  284.89 93.91 1 36 
ATP-dependent zinc metalloprotease FtsH  271.81 59.01 1 34 
ATP-dependent protease ATPase subunit HslU  223.17 58.92 1 27 
ATP-dependent Clp protease ATP-binding subunit ClpX 187.67 74.76 1 26 
ATP-binding component of serine protease  120.06 30.34 1 21 
Uncharacterized ABC transporter ATP-binding protein yjjK 114.09 56.94 1 24 
Lead, cadmium, zinc and mercury-transporting ATPase 105.42 36.20 1 19 
ATP-dependent RNA helicase RhlB  104.31 54.63 1 20 
ATP synthase subunit b  102.74 55.77 1 16 
Oligopeptide transport ATP-binding protein oppD  90.14 51.63 1 13 
ATP synthase gamma chain OS 79.60 60.98 1 15 
ATP-binding component of transport system for maltose 70.79 50.94 1 16 
ATP-independent RNA helicase dbpA 65.04 31.95 1 9 
Oligopeptide transport ATP-binding protein oppF 61.99 41.32 1 13 
ATP synthase subunit delta  52.95 52.54 1 7 
Putative ATP-binding component of a transport system 46.84 65.80 1 9 
Putative ATP-binding component of a transport system  45.41 45.23 1 8 
ATP-dependent RNA helicase hrpA  40.58 9.92 1 10 
ATP-binding component of high- 37.80 46.69 1 8 
ATP-binding component of a membrane 34.28 42.79 1 6 
Holliday junction ATP-dependent DNA helicase RuvB  33.30 34.23 1 7 
Table 3.1 Proteomic analysis of DJ-1 high–MW species.   
Recombinant human WT DJ-1 sucrose fractions enriched with high-MW species were trypsinized to 




Glutamine transport ATP-binding protein glnQ  30.50 33.75 1 6 
Uncharacterized ABC transporter ATP-binding protein ydcT  27.07 23.44 1 5 
Lipoprotein-releasing system ATP-binding protein lolD  24.52 26.18 1 4 
Spermidine/putrescine import ATP-binding protein potA  23.89 26.46 1 6 
ATP-binding/permease protein cydC  18.59 12.91 1 5 
ATP-binding component of 3rd arginine transport system  18.46 33.06 1 4 
Uncharacterized ABC transporter ATP-binding protein 15.34 9.74 1 2 
Dipeptide transport ATP-binding protein dppF  14.15 11.68 1 3 
ATP-dependent transporter sufC 13.45 22.18 1 4 
Uncharacterized ABC transporter ATP-binding protein yejF 13.44 5.10 1 2 
Methionine import ATP-binding protein metN  12.52 13.70 1 2 
Uncharacterized GTP-binding protein yjiA  11.54 11.64 1 3 







CHAPTER 4: INTERPLAY OF DJ-1 AND ATP13A2 IN AUTOPHAGY 
4.1. Introduction  
The localization of ATP13A2 to lysosomal membranes may play a key role in 
modulating autophagy. A loss of ATP13A2 function has been shown to 
compromise lysosomal acidification, decrease proteolytic processing of 
lysosomal enzymes, and reduce the degradation of lysosomal substrates [175]. 
Because dysfunctional mitochondria are degraded via autophagy [144], 
impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a 
buildup of defective mitochondria that produce increased ROS [144, 176]. 
Expression of ATP13A2 protects mammalian cells from oxidative stress and 
dysfunctional mitochondria [177]. In addition, loss of ATP13A2 function in human 
fibroblasts triggers decreased ATP production, mitochondrial genome integrity, 
and increased oxygen consumption and mitochondrial fragmentation [178].  
Loss or mutation of mitochondrial DJ-1 induces an increase in ROS levels, a 
decrease in respiration rates and mitochondrial membrane potential (MMP), and 
a disruption of the critical balance between mitochondrial fusion and fission 





DJ-1 re-localization to mitochondria, a phenomenon associated with protection 
against cytotoxicity [118]. DJ-1 has also been shown to protect neurons from 
rotenone-induced oxidative stress and cell death [155, 156]. 
Aggregated aSyn is eliminated from cells via lysosomal autophagy [164, 175]. In 
addition, aSyn accumulation induces a buildup of ROS which have been shown 
to disrupt lysosomal membrane integrity, ultimately causing cell death [210, 211]. 
Furthermore, methamphetamine (METH), an addictive drug that elicits a PD-like 
neurodegenerative phenotype in the brains of abusers, induces oxidative stress 
and a build-up of autophagic vacuoles (autophagosomes) in neuronal cell lines 
[212, 213]. DJ-1 is known to inhibit aSyn aggregation and toxicity, suppress 
oxidative stress, and stimulate lysosomal autophagy [144, 156, 214].  
The above sections highlight advances in our understanding of DJ-1 and 
ATP13A2 neuroprotective activities. However, whether DJ-1 and ATP13A2 
interact on a functional level to modulate mitochondrial and lysosomal function is 
not known.  We hypothesized that knockdown of DJ-1 or ATP13A2 would disrupt 
lysosomal autophagy by causing a buildup of ROS that permeabilize lysosomal 
membranes. Defects in lysosomal autophagy were characterized by monitoring 
effects of DJ-1 and ATP13A2 knockdown on autophagosome accumulation in 





4.2. Materials and Methods.  
4.2.1 Materials  
The bicinchoninic acid (BCA) protein assay kit was obtained from Pierce 
Biotechnology 
(Rockford, IL). The ECF substrate was purchased from GE Healthcare 
(Piscataway, NJ).  Coomassie Brilliant blue R250 and SDS were obtained from 
Amresco (Solon, OH). Trizma base, 2-mercapto ethanol (2ME), ammonium 
persulfate (APS), glycine, urea, iadoacetamide, sucrose, paraformaldehyde 
(PFA), protease inhibitor cocktail, trypsin and ammonium chloride (NH4Cl)  were 
purchased from Sigma-Aldrich (St. Louis, MO). DTT was purchased from Gold 
Biotechnology, fetal bovine serum (FBS), penicillin-streptomycin, Lipofectamine 
2000, Opti-MEM, Trypsin-EDTA were obtained from Invitrogen (Carlsbad, CA). 
4.2.2 Antibodies 
The following antibodies were used in these studies: mouse anti human DJ-1 
(clone 3E8) (Enzo Life Sciences, Farmingdale, NY), secondary anti mouse IgG 
conjugated with alkaline phosphatase (Promega, Madison, WI, USA), secondary 
anti rabbit IgG conjugated with alkaline phosphatase (Promega, Madison, WI, 
USA). Anti ATP13A2 (Novus Biologicals, Littleton, CO, catalogue # NB110-
41486). 
4.2.3 Preparation of lentiviral and adenoviral constructs 
A lentiviral construct encoding a short hairpin RNAs (shRNAs) was used to 
down-regulate rat DJ-1. An shRNA-encoding cassette spanning amino acid 




pENTR/U6(Invitrogen) and subsequently transferred to the lentiviral vector 
pLenti6/BLOCK-iT DEST (Invitrogen) by recombination [126]. Plasmids encoding 
human shRNA DJ-1 (clone 4918) and human shRNA ATP13A2 (clone BC 
030267) were obtained from Dr. Benjamin Dehay (University of Bordeaux). A 
lentiviral construct encoding rat shRNA ATP13A2 (Open Bio system, Clone ID 
TRCN0000101716) was used to knockdown ATP13A2 protein in N27 cells. A 
non-mammalian shRNA was used as a control plasmid DNA (Sigma Aldrich, Cat. 
SHC002). A cDNA encoding ATP13A2 (clone BC 030267) obtained from Dr. 
Susan Lindquist was ligated into pENTR/U6 and subsequently transferred to the 
adenoviral vector pAd/CMV/V5-DEST (Invitrogen) by recombination [216]. 
4.2.4 Generation of N27 and SH-SY5Y stable cell lines with 
ATP13A2 or DJ-1 knockdown 
N27 rat dopaminergic neuronal cells were plated in the wells of a 6 well plate 
(70,000 cells per well) in RPMI 1640 media with 15% (v/v) FBS and 1% (v/v) 
penicillin-streptomycin (Pen-Strep). The cells were transduced with lentivirus 
encoding rat shRNA ATP13A2 (MOI 5)  or rat shRNA DJ-1 (MOI 50)  An 
additional set of cells was transduced with non-mammalian targeting shRNA 
virus to generate a negative-control stable cell line. After 24-48 h, the media 
containing the virus was replaced with media containing puromycin, a 
mammalian selection marker (final concentration of 2 μg/mL), to select for cells 
that were transduced by the lentivirus. Media with puromycin was replaced with 
fresh media every 2 days for the first week to remove the dead cells, and 




started forming on the plate after about 4-6 weeks. Each colony was carefully 
selected using a glass colony ring, to which a layer of grease was applied on the 
edge facing the plate surface to facilitate attachment of the ring to the plate. The 
colonies were propagated in media containing puromcyin (2 μg/mL), and an 
aliquot of the cells was frozen and stored in a liquid nitrogen tank.  
SH-SY5Y human neuroblastoma cells were plated in the wells of a 6 well plate 
(100,000 cells per well) in RPMI 1640 media with 15% (v/v) FBS and 1% (v/v) 
Pen-Strep. The cells were transfected with a plasmid encoding human shRNA 
DJ-1 and human shRNA ATP13A2 in the presence of Lipofectamine 2000 for 24 
h at 37 ºC. Media containing the transfection reagent was replaced with RPMI 
media without Pen-Strep for 24 h, to allow the cells to recover. The media was 
then replaced with media with Pen-Strep and puromycin (2 μg/mL). The media 
was replaced with fresh media every 2-3 days for about 4-6 weeks, and colonies 
were selected and propagated as described above for the generation of N27 
stably transduced cell lines. Additional sets of cells were transfected with a 
scrambled human shRNA DJ-1 construct or a scrambled human shRNA 
ATP13A2 construct to generate negative-control stable cell lines.   
4.2.5 Acridine Orange (AO) labeling 
To visualize acidic vesicles (e.g. autophagosomes) and lysosomes, cells were 
incubated for 10 min at 37 ºC in an atmosphere containing 5 % (v/v) CO2 in RPMI 
1640 media supplement with AO (1 μg/mL), a lysosomotropic metachromatic 
fluorochrome that emits an intense orange fluorescence after accumulating in 




with phenol-red free media, and the cells were imaged on a confocal microscope 
at 60x magnification (Nikon TE2000-U inverted fluorescence microscope, Nikon 
Instruments, Melville, NY). A decrease in AO fluorescence intensity was 
interpreted to mean an increase in lysosomal membrane permeability (LMP) or 
the permeability of acidic vesicles, suggesting that membrane disruption had 
occurred. 
4.2.6 Western blotting  
Cells were treated with NH4Cl (25 mM) for 4 h (in the case of an 8 h METH 
incubation, NH4Cl was included during the final 4 h). Cells were dislodged from 
the plate by pipetting, collected by centrifugation, washed with phosphate-
buffered saline (PBS)(136 mM NaCl, 0.268 mM KCl, 10 mM Na2HPO4, 1.76 mM 
KH2PO4, pH 7.4), and lysed in RIPA buffer (25 mM Tris–HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 1% (w/v) sodium 
deoxycholate, protease inhibitor cocktail(Sigma), and 1 mM 
phenylmethanesulfonylfluoride (PMSF)). After centrifugation at 13,000 g, the 
detergent-soluble (supernatant) fraction was recovered. The protein 
concentration in the soluble fraction was measured using the BCA Protein Assay 
Kit (Pierce Biotechnology, Rockford, IL, USA), and equal amounts of protein 
were separated via SDS–PAGE on a 4–20% (w/v) polyacrylamide gel. The 
proteins were transferred to a 0.2 μm or 0.45 μm PVDF membrane, which was 
probed  with a monoclonal antibody specific for mammalian aSyn (Syn-1, 
1:1000), DJ-1 (1:250,000), ATP13A2 (1:2000). The secondary antibody was an 




Chemifluorescence images were obtained and analyzed using a Typhoon 
imaging system (GE Health Sciences, Piscataway, NJ, USA). To confirm that 
equal amounts of protein were loaded in all lanes, the blots were reprobed with a 
primary antibody specific for β-actin (1:50000). 
4.2.7. O2 Consumption   
O2 consumption was monitored as described [217]. Stably transduced N27 cells 
were plated in a 10 cm dish. The cells were harvested via centrifugation at 700 x 
g (10 min, 4 ºC) and resuspended in O2 consumption buffer (20 mM HEPES, pH 
7.2). Cellular respiration was measured using a Clark-type oxygen electrode 
attached to a voltmeter (Digital Model 10 Controller, Rank Brothers, Ltd, 
Cambridge, UK). The electrode was allowed to stabilize at 37 °C for 30 min to 
ensure air saturation. To normalize the background current, the voltmeter was 
set to zero using a polarizing voltage of 0.40 V. An aliquot of 1 x 106 cells (400 
μL) was loaded into the respiration chamber, where the sensitivity control was set 
to 1 V. This reflected 100% of the O2 concentration (0.21 mM) in the air-saturated 
reaction medium present before the start of respiration [217]. The sample was 
constantly stirred at 840 rpm using a magnetic stir bar located inside the 
chamber. Using the Pico Technology software program (PicoTechnology, Ltd., 
Cambridgeshire, UK), the O2 level remaining in the chamber at any time during 
respiration was automatically logged (with 10 sec intervals) as a voltage (Vo2). 
The Vo2 reflected the voltage generated by the reaction of O2 with the electrode 
(Vo2 steadily decreased as O2 was consumed) [217]. Percentage O2 response 




4.2.8 Fluorescence microscopy using tandem GFP-RFP-LC3 
construct.  
GFP-RFP-LC3 stable cell lines were generated by Dr. Amy Griggs. In brief, SH-
SY5Y human neuroblastoma cells were plated in the wells of a 6 well plate 
(100,000 cells per well) in RPMI 1640 media with 15% (v/v) FBS and 1% (v/v) 
Pen-Strep.  The cells were transfected with a plasmid encoding GFP-RFP-LC3 in 
the presence of Lipofectamine 2000 for 6 h at 37 ºC. Media containing the 
transfection reagent was replaced with RPMI media without Pen-Strep for 24 h, 
to allow the cells to recover. The media was then replaced with media with Pen-
Strep and G418 (600 μg/mL). The media was replaced with fresh media every 2-
3 days for about 4-6 weeks, and colonies were selected and propagated as 
described in section 4.2.4 above.   
The cells were transduced with adenoviruses encoding WT ATP13A2 or the 
control protein LacZ (MOI of each virus = 50). After 48 h, the cells were 
incubated with METH (200 μM) for 24 h. The cells were fixed with 4% w/v 
paraformaldehyde (PFA) and imaged using a confocal microscope (excitation 
wavelengths, 488 and 594 nm; emission wavelengths, 525 and 617 nm 
respectively). The tandem LC3 construct was used to monitor autophagic flux 
based on a difference in the pH stability of GFP versus RFP [218]. The acidic pH 
in autolysosomes (cellular structures resulting from the fusion of 
autophagosomes with lysosomes) quenches the GFP fluorescence signal, 




4.2.9 RNA isolation and qRT-PCR  
Cells were harvested by centrifugation at 1300 x g for 10 min at 4 ºC. mRNA was 
extracted using the E.Z.N.A total RNA kit I (Omega Bio-Tek). Total RNA (200 ng) 
was reverse-transcribed by the iScript Select cDNA Synthesis Kit (170–8896) 
(Bio-Rad).  Quantitative PCR (qRT-PCR) was performed using the iQ SYBR 
Green PCR Kit (Bio-Rad) using forward and reverse primers specific for 
ATP13A2, DJ-1, or the control GAPDH. ATP13A2, DJ-1 and GAPDH levels were 
normalized and fold change was calculated using the following formula: 
? ?, , , ,( ) ( )2 2 t TG t CG KD t TG t CG controlt C C C CC ? ? ? ???? ?  
Where Ct,TG represents the crossing threshold for the target gene, Ct,CG 
represents the crossing threshold for the target gene, ‘KD’ refers to mRNA 
obtained from ATP13A2 or DJ-1 knockdown cells, and ‘control’ refers to mRNA 
obtained from cells transduced with a control (non-targeting) vector.  
4.3. Results  
4.3.1 Decreased levels of DJ-1 and ATP13A2 mRNA and protein in 
N27 stable knockdown cells.  
To generate N27 rat dopaminergic neuronal cells with a stable knockdown of DJ-
1 or ATP13A2, the cells were transduced with lentivirus encoding shRNA DJ-1 or 
shRNA ATP13A2. Additional cells were transduced with lentivirus encoding non-
mammalian targeting shRNA to generate a control stable cell line. Analysis of the 
N27 shRNA DJ-1 cell lysates by qRT-PCR and Western blotting revealed an 




knockdown in DJ-1 protein levels (Fig 4.1B, C) compared to the control 
knockdown stables.  Analysis of lysates from two clonal lines of N27 shRNA 
ATP13A2 (‘colony 10’ and ‘colony 12’) by qRT-PCR and Western blotting 
revealed a 90% decrease in the level of ATP13A2 mRNA (colony 10 line) (Fig 
4.2A) and a complete loss of ATP13A2 protein in both clonal lines (predicted 
molecular weight, 129 kDa) (Fig 4.2B). Furthermore, we generated both DJ-1 
and ATP13A2 knockdown stables in SH-SY5Y human dopaminergic 
neuroblastoma cells (data not shown). 
4.3.2 N27 ATP13A2 knockdown cells show an increase in LC3 II 
levels. 
Previous studies have reported that cells depleted of ATP13A2 via RNAi-
mediated knockdown exhibit decreased proteolytic processing of lysosomal 
enzymes, reduced degradation of lysosomal substrates, increased mitochondrial 
mass, and increased ROS production [175, 176]. Based on these studies, we 
tested the effect of our generated N27 ATP13A2 knockdown cells on lysosomal 
degradation. We hypothesized that knockdown of ATP13A2 should increase the 
accumulation of autophagosomes. To address this hypothesis, N27 ATP13A2  
knockdown cells (colony 10 and colony 12) and control (non-targeting) stable 
cells were treated with or without METH in the absence or presence of NH4Cl, an 
inhibitor of autophagosome degradation by lysosomes. METH induces oxidative 
stress and a build-up of autophagic vacuoles (autophagosomes) in neuronal cell 
lines [212, 213]. Autophagosomes levels were monitored by measuring levels of 




increased level of LC3 II in lysates from colony 10 cells (Fig 4.3) and colony 12 
cells (Fig 4.4) compared to control cells, in the absence or presence of METH 
(the effect was more pronounced in cells co-treated with METH). For both 
ATP13A2 knockdown clonal cell lines treated with METH, the magnitude of the 
increase in LC3 II levels was dependent on the time of METH treatment (4 h 
versus 8 h).  Similar effects of ATP13A2 knockdown and METH treatment on 
LC3 levels were obtained with ATP13A2 knockdown cells cultured in the 
presence of NH4Cl, except that the LC3 levels in these cell lysates were 
markedly greater. These results suggest that ATP13A2 knockdown in N27 cells 
induces an increase in autophagosome formation and/or disrupts the lysosomal 
degradation pathway, thereby triggering autophagosome accumulation. In 
addition, METH sensitizes the cells to the effects of ATP13A2 knockdown, 
causing further increases in LC3-II autophagosome levels. 
4.3.3 ATP13A2 overexpression enhances autophagosome 
clearance. 
We hypothesized that overexpression of ATP13A2 would enhance the clearance 
of autophagosomes. To address this hypothesis we overexpressed ATP13A2 or 
the control protein LacZ from adenoviral constructs in cells stably expressing a 
‘tandem’, GFP-RFP-LC3 construct that enables one to monitor autophagic flux 
based on the fact that GFP and RFP can both be visualized in autophagosomes, 
whereas GFP (but not RFP) is destabilized (and thus not visible by microscopy) 
in more acidic compartments such as autolysosomes. The results show that 




number of autophagosomes and autolysosomes in METH-treated cells (Fig. 4.5). 
These data suggest that ATP13A2 may enhance autophagosome clearance 
(thus inhibiting autophagosome accumulation) in METH-treated cells, potentially 
by enhancing autophagosome-lysosome fusion and/or lysosomal function [175]. 
4.3.4 ATP13A2 knockdown reduces the METH-induced up-
regulation of acidic cellular compartments.  
A loss of ATP13A2 function has been shown to compromise lysosomal 
acidification [175]. Accordingly, we hypothesized that the knockdown of ATP13A2 
would disrupt lysosomal pH in our cell culture models. To address this 
hypothesis, N27 ATP13A2 knockdown cells were treated with or without METH, 
and levels of lysosomes and acidic organelles (e.g. autophagosomes) were 
monitored using AO, a lysosomotropic metachromatic fluorochrome that emits an 
intense red fluorescence after accumulating in acidic cellular compartments. Our 
results showed that METH induced an increase in AO-positive cellular structures 
in control N27 cells expressing a non-targeting shRNA, whereas this effect was 
suppressed in ATP13A2 knockdown cells (Fig 4.6). These results suggest that 
ATP13A2-deficient N27 cells show a decrease in METH-induced accumulation of 
AO-positive structures, perhaps because of a defect in the acidification of cellular 
compartments on the autophagic or endocytic pathway. 
4.3.5 ATP13A2 knockdown increases levels of mitochondrial 
protein carbonyls. 
The next experiment was designed to determine the effect of ATP13A2 




would increase levels of mitochondrial protein carbonyls, a marker of 
mitochondrial oxidative stress. To address this hypothesis, MES23.5 
dopaminergic neuronal cells were transduced with lentivirus encoding shRNA 
ATP13A2. Mitochondrial fractions were isolated and analyzed for protein 
carbonyls The results showed that cells depleted of ATP13A2 have elevated 
levels of mitochondrial protein carbonyls compared to control (untransduced) 
cells (Fig 4.7). These results suggest that shRNA ATP13A2 sensitizes 
mitochondrial proteins to oxidation, potentially by triggering increases in 
mitochondrial ROS.  
4.3.6 N27 DJ-1 knockdown cells show an increase in LC3-II levels. 
Cells lacking DJ-1 exhibit a decrease in mitochondrial degradation, an increase 
in mitochondrial mass, and an increase in ROS levels [144]. Other studies have 
shown that DJ-1 suppresses the formation of protein carbonyls in rat primary 
midbrain cultures [126]. ROS accumulation may cause lysosomal membrane 
permeability (LMP), thus disrupting lysosomal degradation pathways. 
Accordingly, we hypothesized that DJ-1 knockdown would cause an 
accumulation of autophagic vesicles in neuronal cells. To address this 
hypothesis, N27 DJ-1 knockdown cells and cells stably transduced with a control 
(non-targeting shRNA) vector (section 4.3.1) were treated with or without METH, 
in the absence or presence of NH4Cl.  Autophagosome levels were monitored by 
determining the cellular content of the autophagic marker, LC3-II. Our results 
showed that knockdown of DJ-1 in N27 cells increased levels of LC3-II compared 




pronounced in cells co-treated with METH) (Fig. 4.8). Similar effects of DJ-1 
knockdown and METH treatment on LC3 levels were obtained with DJ-1 
knockdown cells cultured in the presence of NH4Cl, except that the LC3 levels in 
these cell lysates were markedly greater. These results suggest that DJ-1 
knockdown in N27 cells induces an increase in autophagosome formation and/or 
disrupts the lysosomal degradation pathway, thereby triggering autophagosome 
accumulation. In addition, METH sensitizes the cells causing a further increase in 
autophagosome levels. 
4.3.7 N27 cells depleted of ATP13A2 or DJ-1 show a decrease in 
O2 consumption. 
Impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a 
buildup of defective mitochondria that produce increased ROS [144, 176]. On the 
other hand, DJ-1 dysfunction induces an increase in ROS levels, a decrease in 
respiration rates and mitochondrial membrane potential (MMP), and a disruption 
of the critical balance between mitochondrial fusion and fission dynamics [144].  
Based on these studies, we hypothesized that knockdown of either ATP13A2 or 
DJ-1 in N27 cells would disrupt mitochondrial function, hence decreasing the rate 
of O2 consumption. To address this hypothesis, N27 cells depleted of ATP13A2 
or DJ-1 were characterized in terms of their rates of cellular respiration using a 
Clark-type oxygen electrode attached to a voltmeter. The results revealed that 
cells depleted of ATP13A2 or DJ-1 showed a decreased rate of O2 consumption 
compared to control cells transduced with a non-targeting shRNA vector (Fig. 




function results in a disruption of mitochondrial respiration as evident in the 
observed decrease in O2 consumption.   
4.3.8 DJ-1 depletion via shRNA knockdown results in down-
regulation of ATP13A2 expression in N27 cells, and vice-versa. 
Depletion of ATP13A2 or DJ-1 in N27 cells leads to the same biological outcome 
namely, an increase in LC3-II accumulation (Fig 4.3, Fig 4.4 and Fig 4.8). 
Accordingly, we hypothesized that the two proteins might interact on a functional 
level to modulate mitochondrial or/and lysosomal function. As one approach to 
address this hypothesis, we investigated whether the expression levels of 
ATP13A2 and DJ-1 are co-regulated by examining the effects of depleting each 
protein via shRNA-mediated knockdown on the expression level of the other. 
Levels of ATP13A2 mRNA and protein were examined in N27 DJ-1 knockdown 
cells via qRT-PCR and Western blotting, respectively, whereas DJ-1 mRNA 
levels were examined in N27 ATP13A2 knockdown cells via qRT-PCR.  N27 DJ-
1 knockdown cells showed a 90% decrease in ATP13A2 mRNA (Fig. 4.10A) and 
a 90% decrease in ATP13A2 protein (Fig 4.10B) relative to control cells 
transduced with a non-targeting shRNA vector. Levels of DJ-1 mRNA in N27 
ATP13A2 knockdown cells were decreased by 35-40% relative to control cells 
(Fig. 4.11). These results are the first to suggest that DJ-1 and ATP13A2 are co-




4.3.9 DJ-1 is down-regulated in primary midbrain cultures depleted 
of ATP13A2, whereas ATP13A2 is up-regulated in midbrain 
cultures depleted of DJ-1. 
Additional experiments were carried out to determine whether ATP13A2 and DJ-
1 are co-regulated in rat primary midbrain cultures. On the basis of results 
obtained with N27 knockdown cells (4.3.8), we hypothesized that midbrain 
cultures depleted of DJ-1 would exhibit a decrease in ATP13A2 expression 
levels, and vice versa. To address this hypothesis, primary mid brain cultures 
transduced with lentivirus encoding a DJ-1 shRNA or an ATP13A2 shRNA were 
analyzed by qRT-PCR to determine levels of ATP13A2 and DJ-1 mRNAs.  The 
results showed an approximately 72% decrease in DJ-1 mRNA levels in cultures 
depleted of ATP13A2 (70% knockdown of ATP13A2 mRNA) compared to control 
cultures (Fig 4.12). Surprisingly, we observed a 70% increase in ATP13A2 
mRNA levels in cultures depleted of DJ-1 (72% knockdown of DJ-1 mRNA) 
compared to control cultures (Fig 4.13).  Collectively, these data provide 
evidence that DJ-1 and ATP13A2 are co-regulated in rat primary midbrain 
cultures.   
 
4.4. Discussion 
4.4.1 Knockdown of ATP13A2 causes LC3-II accumulation.  
A loss of ATP13A2 function causes impaired lysosomal acidification [175]. 
Autophagosomes fuse with lysosomes to degrade or recycle their components. 




Disruption of this process leads to an accumulation of autophagosomes. Our 
data showed an increase in LC3-II levels in N27 ATP13A2 knockdown cells, and 
this effect was enhanced in the presence of METH. These results suggest, as 
one possibility, that ATP13A2 knockdown elicits an increase in lysosomal pH, 
resulting in inhibition of autophagosome-lysosome fusion and thus 
autophagosome accumulation, as evident by increased LC3-II levels. Additional 
results revealed a time-dependent increase in LC3-II levels in N27 ATP13A2 
knockdown cells and control cells cultured in the presence versus the absence of 
METH. METH has been shown to induce oxidative stress by increasing the levels 
of ROS in striatal, mesencephalic and cortical astrocytes [219]. Furthermore, 
METH induces neurotoxicity in dopamine neurons by disrupting dopamine 
sequestration in synaptic vesicles leading to oxyradical stress, autophagy and 
neurite degeneration [220]. In addition, impairment of autophagy resulting from 
ATP13A2 depletion is thought to trigger a buildup of defective mitochondria that 
produce increased ROS [144, 176]. ROS causes lysosomal membrane 
permeability (LMP), disrupting lysosomal function [221]. Therefore, we infer that 
METH-induced accumulation of autophagosomes may reflect up-regulation of 
autophagy and/or a disruption of autophagosome-lysosome fusion, and both 
effects could be enhanced by ATP13A2 depletion. ATP13A2 dysfunction could 
lead to induction of autophagy based on NH4Cl results (NH4Cl combined with 
ATP13A2 KD gives much higher LC3-II levels than NH4Cl in control cells). This 
could be an indirect effect of oxidative stress leading to proteasome inhibition 




4.4.2 ATP13A2 overexpression enhances lysosomal clearance in 
SH-SY5Y cells. 
ATP13A2 overexpression has been shown to rescue zinc toxicity and promote  
mitochondrial fusion in human olfactory neurosphere cultures [183]. Additional 
evidence suggests that ATP13A2 enhances autophagic flux and inhibit 
autophagosome accumulation, potentially by enhancing lysosomal function 
and/or autophagosome-lysosome fusion [175]. Here, we showed using SH-SY5Y 
cells expressing a tandem GFP-RFP-LC3 construct that METH induced an 
increase in the relative number of puncta that emitted red and green 
fluorescence (corresponding to autophagosomes) or only red fluorescence 
(corresponding to autolysosomes), and this effect was diminished in cells 
overexpressing ATP13A2. These results suggest that overexpression of 
ATP13A2 enhances autophagosome clearance, perhaps via a mechanism 
involving enhanced lysosome acidification resulting in increased 
autophagosome-lysosome fusion and/or lysosomal degradation. It is also 
possible that ATP13A2 over-expression results in a decrease in METH-induced 
autophagosome formation via an indirect mechanism involving alleviation of 
oxidative stress. 
4.4.3 Knockdown of ATP13A2 disrupts autophagy and lysosomal 
pH.  
The results of AO staining experiments showed a METH-dependent increase in 
the relative number of red puncta corresponding to acidic vesicles or organelles 




knockdown cells. Examples of cellular structures that could take up the AO stain 
include autophagosomes [224], macropinosomes [225], or lysosomes. Our 
results suggest that there is a decrease in the acidification of these structures in 
cells depleted of ATP13A2. A disruption of lysosomal pH would be predicted to 
cause an accumulation of autophagosomes, and thus the AO staining data are 
consistent with data showing that LC3-II-positive vesicles accumulate in 
ATP13A2 knockdown cells (see above).   
4.4.4 ATP13A2 knockdown increases levels of protein carbonyls in 
ME23.5 cells. 
Impairment of autophagy resulting from ATP13A2 depletion is thought to trigger a 
buildup of defective mitochondria that produce increased ROS [144, 176]. Here 
we showed that knockdown of ATP13A2 in MES23.5 cells increased the level of 
mitochondrial protein carbonyls, an indicator of oxidative stress. Based on the 
data presented here (see above) and by other groups [175] that ATP13A2 is 
involved in lysosomal autophagy, we infer that the increase in the levels of 
mitochondrial protein carbonyls in ATP13A2 knockdown cells reflects a buildup of 
dysfunctional mitochondria. Normally, dysfunctional mitochondria would be 
degraded via mitophagy, a process involving mitochondrial uptake by a 
phagophore that develops into an autophagosome which in turn fuses with a 
lysosome. Impairment of lysosome acidification is expected to lead to an 
accumulation of autophagosomes and a buildup of dysfunctional mitochondria 




lysosomal impairment, disruption of mitophagy, accumulation of dysfunctional 
mitochondria, and oxidative stress. 
4.4.5 Knockdown of DJ-1 disrupts lysosomal function thus 
increasing autophagosome accumulation.  
Loss or mutation of mitochondrial DJ-1 induces an increase in ROS levels, a 
decrease in respiration rates and mitochondrial membrane potential (MMP), and 
a disruption of the critical balance between mitochondrial fusion and fission 
dynamics [144]. Knockdown of DJ-1 in both N27 cells and SH-SY5Y cells 
increased levels of autophagosomes as evident from Western blotting data 
showing an increase in cellular LC3-II content.  An increase in LC3-II content 
might be due to disrupted lysosomal function, leading to inefficient 
autophagosome elimination via the lysosomal degradation pathway. The 
increase in LC3-II levels was enhanced in N27 cells depleted of DJ-1 upon 
treatment of the cells with METH. We attribute this outcome to a disruption of 
autophagosome-lysosome fusion caused by ROS-induced LMP, a phenomenon 
that could result from oxidative stress associated with DJ-1 knockdown and 
METH exposure [161].  We can also infer that DJ-1 contributes to the up-
regulation of autophagy triggered by METH, perhaps as a cellular defense 
mechanism involving Erk-dependent signaling [144]. In addition, we infer that 
METH-induced accumulation of autophagosomes may reflect METH-induced up-




4.4.6 N27 cells depleted of ATP13A2 or DJ-1 exhibit decreased 
rates of cellular respiration.  
N27 cells stably transduced with an shRNA construct targeting ATP13A2 or DJ-1 
showed a decrease in O2 consumption compared to control cells. In contrast, 
human mutant ATP13A2 fibroblasts showed an increase in O2 consumption 
compared to control fibroblasts [178].  A key difference between N27 cells and 
fibroblasts is that only the N27 cells produce dopamine. Cytosolic dopamine 
undergoes auto-oxidation to form dopamine o-quinone, a process that leads to a 
buildup of ROS [18]. In turn, dopamine o-quinone forms adducts with Parkin (a 
protein involved in mitochondrial quality control) [226] and subunits of 
mitochondrial complex I [40, 227].  Therefore, we infer (as one possibility) that 
the decrease in O2 consumption in N27 cells depleted of ATP13A2 could be due 
to a buildup of mitochondria that have become dysfunctional (at least in part) via 
a mechanism involving damage to mitochondrial proteins by dopamine o-
quinone. In contrast, the increase in O2 consumption in ATP13A2 mutant 
fibroblasts presumably reflects a compensatory response to a reduction in ATP 
levels in these cells [178]. 
4.4.7 ATP13A2 and DJ-1 show evidence of co-regulated 
expression.  
Our findings from studies of N27 cells depleted of ATP13A2 and DJ-1 suggest 
that the two proteins may share a common (or partially overlapping) 
neuroprotective pathway. Consistent with this idea, data obtained by qRT-PCR 




knockdown cells, and vice versa. Similarly, there was a decrease in DJ-1 mRNA 
levels in primary midbrain cultures depleted of ATP13A2 by shRNA-mediated 
knockdown. These results, the first to show that ATP13A2 and DJ-1 are co-
regulated, suggest that expression of the genes encoding the two proteins might 
be modulated by a common transcription factor that binds to shared promoter 
motifs. Contrarily, we found that ATP13A2 mRNA increased in primary midbrain 
cultures depleted of DJ-1 by shRNA-mediated knockdown. These results suggest 
that the gene expression patterns of ATP13A2 and DJ-1 in N27 cells versus 
primary midbrain cultures are overlapping but non-identical, perhaps reflecting 
differences in N27 gene expression patterns associated with immortalization 
and/or the fact that primary midbrain cultures consist of a mixture of glial and 
neuronal cell types. The fact that ATP13A2 expression is increased in primary 
midbrain cultures implies that ATP13A2 up-regulation may have evolved as a 
protective mechanism to alleviate toxic effects of DJ-1 down-regulation (e.g. 
oxidative stress, disrupted autophagy) in neuronal and/or glial cells. Further 
studies are needed to address whether DJ-1 over-expression can rescue cellular 
dysfunction associated with ATP13A2 knockdown, and vice versa.  
 
4.5 Conclusion 
The data outlined in this chapter suggest that ATP13A2 and DJ-1 both regulate 
lysosomal autophagy. Knockdown of either protein increased LC3-II levels, 
suggesting an accumulation of autophagosomes. Furthermore, we showed that 




DJ-1. This effect can be attributed to increases in ROS that could in turn trigger 
LMP, thereby disrupting lysosomal-autophagosome fusion. Finally, gene 
expression data suggest that (i) ATP13A2 and DJ-1 are co-regulated in N27 
cells, and (ii) neurotoxic effects of DJ-1 depletion may be rescued by ATP13A2 
up-regulation in primary midbrain cultures. These findings are important because 
they shed light on the role of lysosomal autophagy in ATP13A2- and DJ-1-
mediated protection against neurotoxicity elicited by METH. In addition they 
provide insight into the biochemical mechanism by which DJ-1 preserves 
mitochondrial function in neurons exposed to PD-related insults, and they 






Figure 4.1 Levels of DJ-1 mRNA and protein in N27 stable knockdown cells.  
A. qRT-PCR data showing reduced DJ-1 mRNA levels in N27 DJ-1 knockdown cells versus control cells.  
B. N27 cells were stably transduced with a lentivirus encoding an shRNA specific for DJ-1 or a control 
shRNA that does not target any mammalian genes. Lysates from control and DJ-1 knockdown cells (one 
clonal line of each) were analyzed via Western blotting (30 μg of protein per lane) using primary antibodies 

































Figure 4.2 Levels of ATP13A2 mRNA and protein in N27 stable knockdown cells.  
A. qRT-PCR data showing reduced ATP13A2 mRNA levels in N27 ATP13A2 knockdown cells (colony 
10) versus control cells.  B. N27 cells were stably transduced with a lentivirus encoding an shRNA 
specific for ATP13A2 or a control shRNA that does not target any mammalian genes. (“Ctrl”). Lysates 
from control cells (one clonal line) and ATP13A2 knockdown cells (two clonal lines: colony 10 [col 10] 
and colony 12 [col 12]) were analyzed via Western blotting (30 μg of protein per lane) using primary 























Figure 4.3 ATP13A2 knockdown in N27 cells (colony 10) induces up-regulation of the autophagy 
marker, LC3-II. 
 
 (A) N27 ATP13A2 knockdown cells (colony 10, ‘Col 10’) and control cells transduced with a non-targeting 
shRNA vector were cultured in the absence or presence of METH for 4 h or 8 h. Cell lysates were analyzed via 
Western blotting (30 μg of protein per lane) using primary antibodies specific for LC3 and beta-actin. (B) Bar 
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Figure 4.4 ATP13A2 knockdown in N27 cells (colony 12) induces up-regulation of the autophagy 
marker, LC3-II.  
 
(A) N27 ATP13A2 knockdown cells (colony 12, ‘Col 12’) and control cells transduced with a non-targeting 
shRNA vector were cultured in the absence or presence of METH for 4 h or 8 h. Cell lysates were 
analyzed via Western blotting (30 μg of protein per lane) using primary antibodies specific for LC3 and 
beta-actin. (B) Bar graph showing LC3-II band intensities normalized to the β-actin signal (relative to a 
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Figure 4.5 METH-induced autophagosome accumulation is suppressed in SH-SY5Y cells expressing 
ATP13A2.  
 
SH-SY5Y cells stably expressing a ‘tandem’ GFP-RFP-LC3 construct were untreated (A); treated with METH 
(200 μM) for 24 h (B); or transduced with adenovirus encoding LacZ (C) or ATP13A2 (D) (MOI of each virus 
= 50) for 48 h before being treated with METH for 24 h. The cells were imaged by fluorescence microscopy. 
Puncta that emit GFP and RFP fluorescence are thought to correspond to autophagosomes, whereas puncta 






Control No METH Control + 200 μM METH 
ATP13A2 KD No METH ATP13A2 KD + 200 μM METH 
A B 
Figure 4.6 ATP13A2 is involved in the METH-induced accumulation of acidic vesicles or organelles.   
 
A. Images showing different levels of red puncta corresponding to acidic vesicles or organelles in N27 ATP13A2 
knockdown cells and in control cells transduced with a non-targeting shRNA vector. The cells were treated with or 
without METH (200 μM, 8 h) and subsequently incubated with acridine orange (AO) (1 μg/mL, 10 min), a 
fluorescent dye that emits red fluorescence when taken up by acidic vesicles or organelles   Live cells were 
imaged in phenol red-free media by fluorescence microscopy. B. Bar graph showing relative numbers of acidic 
vesicles or organelles in N27 ATP13A2 knockdown cells or control cells treated as described in panel A. For each 
set of cells, regions of interest were drawn around invidual red puncta and scored for mean fluorescence intensity. 
The data are presented as the percentage of puncta with a mean intensity greater than a threshold value, defined 
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Figure 4.7 Knockdown of ATP13A2 triggers an increase in the oxidation of mitochondrial 
proteins.  
 
(A) MES23.5 cells were transduced with shPark9 lentivirus (MOI 50). Mitochondrial fractions were 
isolated after 72 h and analyzed for protein carbonyl levels using the OxyBlot kit (Millipore). The image 
shows the resulting Western blot (9 μg of protein per lane) probed with an antibody specific for 2,4 
dinitrophenylhydrazone (DNP). (B) Bar graph showing protein carbonyl band intensities normalized to 



















Figure 4.8 DJ-1 knockdown in N27 cells induces up-regulation of the autophagy marker, 
LC3-II.  
 
(A) N27 DJ-1 knockdown cells and control cells transduced with a non-targeting shRNA vector were 
cultured in the absence or presence of METH for 4 h or 8 h. Cell lysates were analyzed via Western 
blotting (30 μg of protein per lane) using primary antibodies specific for LC3 and beta-actin. (B) Bar 
graph showing LC3-II band intensities normalized to the β-actin signal (relative to a value of 1 for 






















































Figure 4.9 N27 cells depleted of DJ-1 or ATP13A2 have reduced rates of O2 consumption. 
N27 cells stably transduced with a lentiviral construct encoding an shRNA specific for ATP13A2 or DJ-1, 
and control cells transduced with a non-targeting shRNA vector, were analyzed for O2 consumption rates 



































Figure 4.10 ATP13A2 mRNA and protein levels are decreased in N27 cells depleted of DJ-1. 
 
(A) Bar graph showing ATP13A2 mRNA levels determined via qRT-PCR in N27 DJ-1 knockdown 
cells and in control cells (relative to a value of 1 for control cells). (B) Lysates from N27 DJ-1 
knockdown cells and control cells transduced with a non-targeting shRNA vector were analyzed via 













Figure 4.11 DJ-1 mRNA levels are decreased in N27 cells depleted of ATP13A2. 
  
The bar graph shows DJ-1 mRNA levels determined via qRT-PCR in N27 ATP13A2 











 Figure 4.12 DJ-1 mRNA levels are decreased in rat primary midbrain cultures depleted of 
ATP13A2.  
 
The bar graph shows DJ-1 mRNA levels determined via qRT-PCR in primary midbrain cultures 
transduced with lentivirus encoding a control (non-targeting) shRNA or an shRNA specific for DJ-1 or 












Figure 4.13 ATP13A2 mRNA levels are increased in rat primary midbrain cultures depleted of DJ-1.  
The bar graph shows ATP13A2 mRNA levels determined via qRT-PCR in primary midbrain cultures 
transduced with lentivirus encoding a control (non-targeting) shRNA or an shRNA specific for DJ-1 or 





CHAPTER 5: DISCUSSION 
5.1. Summary of our research  
The monomeric subunit of DJ-1 is highly homologous to the Pyrococcus 
horikoshii 1704 gene product (PH1704), a bacterial cysteine protease which 
forms a hexamer. DJ-1 has an additional α helix (helix H8) at the C-terminus 
compared to PH1704. A recent study has shown that a truncated form of DJ-1 
(15 amino acids cleaved at the C terminus, resulting in the removal of helix H8) 
has much greater protease activity compared to full length DJ-1 [46]. This C-
terminally truncated form of DJ-1 (DJ-1Δ15) was found to accumulate in 
dopaminergic cells exposed to oxidative stress, leading Chen et al. [46] to 
conclude that full-length WT DJ-1 is in fact a zymogen that becomes activated 
via a redox-sensitive cleavage mechanism. Importantly, however, it is not known 
whether DJ-1Δ15 has the ability to form a hexamer, or whether such a hexameric 
structure is responsible for the observed protease activity. Based on the 
structural similarity of DJ-1Δ15 and PH1704, we proposed in Chapter 2  that DJ-
1Δ15 can form functional hexamers as a result of removal of the C-terminal 15 
residues, and this oligomerization could allow for the formation of a new interface 
necessary for the assembly of a trimer of dimers. In contrast, full length DJ-1 




this hypothesis, we purified DJ-1Δ15 from an E.coli expression system. The 
protein was analyzed via a native PAGE and AUC, and a predicted three-
dimensional structure of DJ-1Δ15 was examined using PyMOL. Our results 
showed that DJ-1Δ15 can potentially form high order oligomeric species. 
Specifically, the results of our Pymol analysis revealed that DJ-1Δ15 has the 
ability to form a closed hexamer by forming a new interface (patch 1’). In 
contrast, full-length DJ-1 cannot adopt a hexameric structure due to steric 
conflicts involving helix 8, as expected. Formation of the DJ-1Δ15 hexamer 
brings a glutamate residue at position 84 in proximity to the catalytic site to 
potentially form a catalytic triad with residues C106 and H126. In addition, the 
results of AUC analyses revealed that the formation of high-order oligomeric 
species by DJ-1Δ15 is concentration-dependent. 
Oxidative stress can cause mitochondrial dysfunction through S-glutathionylation 
of mitochondrial proteins, including F0F1 ATP synthase, thus decreasing their 
activity [228]. Furthermore, glutathione-S-transferases (GSTs) have been shown 
to protect cells against oxidative stress [229].  In Chapter 3 we reported that high 
molecular weight (high-MW) species immunoreactive with a DJ-1 antibody are 
present in our preparations of recombinant, human WT DJ-1 (purified initially as 
a GST fusion protein prior to removal of the GST tag via proteolytic cleavage). 
These high-MW species have ATPase activity and appear as ring-like structures 
when examined by electron microscopy. In contrast, purified GST lacks both 
ATPase activity and ring-like structures. Interestingly, a proteomics study 




rat mesencephalic cell line [205]. The biochemical function of DJ-1 is unknown. 
Our results show that DJ-1 interacts with E.coli F1 ATP synthase, and that the 
reduced form of DJ-1 is preferentially involved in this interaction. These results 
provide new insights into the biochemical mechanism by which DJ-1 preserves 
mitochondrial function in neurons exposed to PD-related insults – namely, by 
interacting with F1 ATPase, a protein complex that is structurally and functionally 
well conserved between E. coli and eukaryotic mitochondria. 
ATP13A2 knockdown has been shown to decrease proteolytic processing of 
lysosomal enzymes, reduce degradation of lysosomal substrates, increase 
mitochondrial mass, and increase ROS production [175, 176].  Cells lacking DJ-1 
exhibit a decrease in mitochondrial clearance (mitophagy), an increase in 
mitochondrial mass and an increase in ROS levels [144]. In Chapter 4, we 
examined the functional interplay between ATP13A2 and DJ-1 in neuronal cells 
exposed to a PD-related stress,  METH, a drug that imposes a burden on the 
autophagy clearance system in dopaminergic neuronal cells [230, 231]. We 
hypothesized that knockdown of ATP13A2 or DJ-1 in N27 dopaminergic cells 
would disrupt lysosomal degradation, leading to an increase in LC3-II, an 
autophagosome marker. Our results showed that ATP13A2 knockdown in N27 
cells led to an increase in LC3-II. This increase was further enhanced with the 
addition of METH in the absence or presence of NH4Cl, an agent that disrupts 
lysosomal pH. Because ATP13A2 is a lysosomal ATPase that is known to acidify 
lysosomes [175], our data suggest that the increase in LC3-II-positive 




precludes autophagosome-lysosome fusion [232]. Furthermore, N27 cells 
depleted of ATP13A2 showed a decrease in red puncta staining using AO, a dye 
that accumulates in acidic vesicles (pH<4). In addition, overexpression of 
ATP13A2 interfered with the METH-induced up-regulation of autophagosomes 
and autolysosomes in SH-SY5Y dopaminergic neuronal cells. These results 
suggest that ATP13A2 may enhance autophagic clearance and inhibit 
autophagosome accumulation in METH-treated cells, potentially by enhancing 
autophagosome-lysosome fusion and/or lysosomal degradation [175]. Likewise, 
N27 DJ-1 knockdown cells exhibited increased levels of LC3-II. Previous results 
have shown that cells lacking DJ-1 exhibit a decrease in mitochondrial clearance, 
an increase in mitochondrial mass, and an increase in ROS levels [144]. ROS 
accumulation could disrupt the lysosomal membrane [161]. Therefore, our data 
suggest that N27 DJ-1 knockdown cells have high basal levels of ROS that 
cause disruption of the lysosomal membrane and hence prevent the fusion of 
autophagosomes with lysosomes. METH may enhance this disruption of 
autophagy by triggering additional oxidative stress. In addition, DJ-1 might be 
enhancing clearance of the autophagosomes.  
To analyze the effects of DJ-1 or ATP13A2 knockdown on mitochondrial 
respiration, the rate of O2 consumption was measured on in intact cells. Our 
results showed a decrease in O2 consumption for N27 cells depleted of either 
ATP13A2 or DJ-1. Dopaminergic neurons contain high levels of ROS due to the 
presence of dopamine. Dopamine undergoes auto-oxidation to the o-quinone 




dopaminergic neurons have higher basal levels of oxidative stress than other 
types of neurons, they are more susceptible to pathogenic mechanisms that 
further up-regulate ROS, including mitochondrial dysfunction. Interestingly, 
another group reported that fibroblasts from human patients with an ATP13A2 
mutation exhibit increased O2 consumption rates compared to control fibroblasts. 
These data suggest that dopamine auto-oxidation may render dopaminergic 
neuronal cells more vulnerable to a build-up of dysfunctional mitochondria as a 
result of a loss of ATP13A2 or DJ-1 function. Dopamine auto-oxidation should 
result in the formation of o-quinones that disrupt complex 1 in dopaminergic 
neuronal cells, and this effect could be enhanced by the accumulation of 
dysfunctional mitochondria as a result of mitophagy impairment in cells depleted 
of ATP13A2 or DJ-1. In additional experiments, we sought to determine whether 
ATP13A2 and DJ-1 interact on a functional level to modulate mitochondrial 
or/and lysosomal function. We found that ATP13A2 mRNA and protein were 
down-regulated in N27 DJ-1 knockdown cells, and levels of DJ-1 mRNA were 
reduced in N27 ATP13A2 knockdown cells. These results suggest that DJ-1 and 
ATP13A2 are co-regulated in N27 cells. In contrast, ATP13A2 mRNA was 
increased in rat primary midbrain cultures depleted of DJ-1 via shRNA 
knockdown. These results suggest that the gene expression patterns of 
ATP13A2 and DJ-1 in N27 cells versus primary midbrain cultures are overlapping 
but non-identical, perhaps reflecting differences in N27 gene expression patterns 
associated with immortalization and/or the fact that primary midbrain cultures 




primary midbrain cultures implies that ATP13A2 may have evolved as a 
protective mechanism to alleviate toxic effects of DJ-1 down-regulation (e.g. 
oxidative stress, disrupted autophagy) in neuronal and/or glial cells.  
5.2. Future directions  
5.2.1 To determine whether E84A is a member of a catalytic triad in 
hexameric DJ-1Δ15. 
In Chapter 2, we reported that hexamer formation by DJ-1Δ15 might bring a 
glutamate residue 84 from one subunit (E84) into a position suitable for forming a 
catalytic triad with cysteine 106 (C106) and histidine 126 (H126) form a second 
subunit. Formation of the catalytic triad could be essential for the ability of DJ-
1Δ15 to function as a protease. To determine whether E84 is important for the 
protease activity of DJ-1Δ15, we have generated a construct with E84 mutated to 
alanine (DJ-1Δ15-E84A). Future experiments will be aimed at examining the 
protease activity of this mutant. If E84A shows a loss of protease activity, then 
we will infer that DJ-1-Δ15 adopts a hexameric structure to enable the assembly 
of a catalytic triad essential for protease function, similar to PH1704 [112]. If our 
prediction is incorrect, then we will infer that the formation of a catalytic triad 
involving E84 is not essential for the protease activity of DJ-1-Δ15. A potential 
limitation is that DJ-1-Δ15 may fail to form a stable hexamer as a result of C106 
over-oxidation. In this case, we will repeat the experiment with DJ-1Δ15-C106A 
and/or DJ-1Δ15-C106D. The findings from this study will provide more insights 
into how DJ-1Δ15 carriers out a protease function by revealing information about  




Ultimately it may be possible to develop inhibitors to test the biological role of this 
protease. 
5.2.2 To determine whether GST modulates interactions of DJ-1 
with F1 ATP synthase. 
In Chapter 3, we determined that recombinant; human WT DJ-1 (purified initially 
as a GST fusion protein prior to removal of the GST tag via proteolytic cleavage) 
contained high molecular weight (high-MW) species immunoreactive with DJ-1 
antibodies. The presence of these high-MW species correlates with (i) the 
presence of ring-like structures that can be visualized by TEM, and (ii) the 
presence of ATPase activity in our DJ-1 preparations. We inferred that the high-
MW species observed in these preparations consisted of a complex of DJ-1 with 
F1 ATP synthase. In contrast, untagged recombinant human WT DJ-1 purified via 
ion-exchange chromatography did not contain high-MW, DJ-1-immunoreactive 
species or show ATPase activity (data not shown). Based on these results, a 
future goal will be to determine the role of GST in modulating the interaction 
between DJ-1 and F1 ATP synthase.  
To assess whether DJ-1 interacts with GST, a pull-down experiment will 
be carried out by incubating recombinant untagged DJ-1 with GST bound to a 
resin with covalently linked glutathione (GSH). The protein material isolated using 
the pull-down approach will be analyzed via Western blotting using antibodies 
specific to DJ-1 and GST. To examine whether GST co-purifies with DJ-1 and/or 
F1 ATP synthase, GST and untagged DJ-1 will be co-expressed in E.coli cells 




activity and for the presence of F1 ATP synthase subunits, GST, and DJ-1 via 
Western blotting. Evidence of ATPase activity and of ATP synthase subunits, 
GST, and DJ-1 in the affinity-purified protein would suggest that DJ-1 and F1 ATP 
synthase form a complex with GST. To further address this hypothesis, the 
purified protein will be analyzed via mass spectrometry. Previous studies have 
shown that in the presence of oxidative stress, F1 ATP synthase subunits are 
glutathionylated, thus decreasing their activity [228]. In addition, cysteine 
oxidative post-translational modifications (for example, disulfide bond formation 
within) the ATP synthase complex cause conformational changes that modulate 
its activity [233]. Furthermore, Drosophila glutathione S-transferase Omega 1 
(GSTO) rescued glutathionylated ATP synthase beta subunit, thus enhancing its 
activity [229]. Glutathionylation, deglutathionylation and other post translational 
modifications of mitochondrial ATP synthase subunits are important for these 
proteins to function under oxidative stress conditions. Therefore, results from our 
studies will shed more light on mechanism for DJ-1 neuroprotection in 
mitochondria. First, DJ-1 may modulate ATP synthase activity by protecting 
against glutathionylation through its interaction with ATP synthase, second, in the 
presence of GST, DJ-1 may deglutathionylate ATP synthase subunits. Third, 
GST may modulate the DJ-1-F1 ATP synthase interaction. 
5.2.3 To determine the effects of aSyn on F1 ATPase activity. 
A proteomics study revealed that aSyn interacts with the α- and β-subunits of F1 
ATP synthase in a rat mesencephalic cell line [205]. To examine the effects of 




be incubated in the absence or presence of aSyn and tested for ATPase activity. 
If we find that aSyn inhibits the ATPase function, then the F1 ATP synthase 
complex will be pre-incubated with aSyn in the absence or presence of DJ-1 and 
re-tested for ATPase activity. As a complementary approach, the effects of aSyn 
on the ATPase activity associated with recombinant DJ-1 (purified as a GST 
fusion protein prior to removal of the GST tag via proteolytic cleavage) will be 
examined. These data will provide insight into how aSyn elicits mitochondrial 
dysfunction and the mechanism by which DJ-1 carries out its neuroprotective 
function. 
5.2.4 To determine the effects of DJ-1 or ATP13A2 expression on 
LC3-II accumulation and mitochondrial respiration. 
Future efforts will be directed towards testing the effects of over-expressing DJ-1 
or ATP13A2 in N27 cells depleted of either protein. We predict that DJ-1 or 
ATP13A2 expression will rescue defects in autophagosome-lysosome fusion in 
ATP13A2 or DJ-1 knockdown cells, respectively. We also predict that defects in 
mitochondrial respiration will be rescued by over-expression of DJ-1 in ATP13A2 
knockdown cells (and vice versa). If this is true, then we will infer that both 
proteins act in concert to alleviate mitochondrial dysfunction and/or the 
accumulation of defective mitochondria triggered by PD-related insults. 
5.2.5 To determine the effects of DJ-1 or ATP13A2 expression on 
aSyn stability.  
Aggregated aSyn is eliminated from cells via lysosomal autophagy [164, 175]. In 




to disrupt lysosomal membrane integrity, ultimately causing cell death [210, 234]. 
DJ-1 is known to inhibit aSyn aggregation and toxicity, suppress oxidative stress, 
and stimulate lysosomal autophagy [144, 156, 214]. We predict that DJ-1 and 
ATP13A2 interact functionally to inhibit aSyn aggregation and neurotoxicity. To 
address this hypothesis, N27 cells depleted of ATP13A2 will be transduced with 
an adenovirus encoding DJ-1, whereas DJ-1 knockdown cells will be transduced 
with an adenovirus encoding ATP13A2 (both sets of cells will be co-transduced 
with aSyn virus). As controls, cells depleted of ATP13A2 or DJ-1 will be 
transduced with LacZ virus (instead of virus encoding DJ-1 or ATP13A2). The 
effects of DJ-1 or ATP13A2 over-expression on aSyn stability, lysosomal 
membrane integrity, and autophagosome accumulation will be evaluated. We 
predict that DJ-1 or ATP13A2 over-expression will rescue defects in aSyn 
stability, lysosomal membrane integrity, and autophagosome-lysosome fusion in 
ATP13A2 or DJ-1 knockdown cells, respectively. If this is true, then we will infer 
that DJ-1 and ATP13A2 act as part of a common pathway to preserve lysosomal 
autophagy and ensure the lysosomal clearance of toxic aSyn aggregates (Fig. 
5.1). Preliminary data from an experiment involving ATP13A2 knockdown in 
dopaminergic neuronal cells suggest that ATP13A2 plays a role in modulating 
aSyn accumulation (Fig. 5.2). Consistent with this finding, evidence suggests that 




5.2.6 To determine the effects of DJ-1 or ATP13A2 knockdown on 
aSyn degradation. 
We predict that DJ-1 and ATP13A2 cooperate to promote aSyn degradation. To 
address this hypothesis, lysosomes will be isolated from N27 cells depleted of 
ATP13A2 or DJ-1 via centrifugation of a mitochondrial-lysosomal fraction through 
a discontinuous metrizamide density gradient [235]. Lysosomes will be incubated 
with radiolabeled aSyn and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), a protein that will serve as a positive control [235]. After precipitating 
the proteins with trichloroacetic acid, the degree of proteolysis will be calculated 
as the percentage of the initial acid-insoluble radioactivity (protein) transformed 
into acid-soluble radioactivity (amino acids and small peptides resulting from 
protein degradation) [236]. The data will indicate whether lysosomes isolated 
from cells depleted of ATP13A2 or DJ-1 have a reduced ability to degrade aSyn 
in a cell-free system, which will serve as a model of chaperone-mediated 
autophagy [237]. We predict that lysosomes isolated from cells depleted of 
ATP13A2 may be dysfunctional as a result of acidification defects and thus may 
exhibit a decreased rate of aSyn clearance via autophagy. In addition, we predict 
that lysosomes isolated from cells depleted of DJ-1 may be damaged by 
oxidative stress and thus may exhibit a decreased rate of aSyn degradation. If 
these predictions are validated, then we will infer that the function of ATP13A2 
and/or DJ-1 is necessary for aSyn degradation via lysosomal autophagy (i.e. 




In addition, the rates of aSyn degradation in N27 cells depleted of ATP13A2 or 
DJ-1 or in control cells will be assessed via pulse pulse-chase analysis. The cells 
will be labeled with 35S-methionine (pulse), washed with buffer, and incubated in 
fresh media with excess unlabeled methionine (chase). The half-life of aSyn will 
be estimated from exponential decay curves of radioactivity versus time. 
Collectively, our findings may support a model in which ATP13A2 and DJ-1 
protect against the neurotoxicity of PD-related insults by suppressing the 
accumulation of dysfunctional mitochondria and ROS production, thereby 









Figure 5.1 Proposed model for DJ-1 and ATP13A2 neuroprotective interplay.  
 
DJ-1 maintains lysosomal membrane integrity by inhibiting mitochondrial dysfunction and ROS 
accumulation. Expression of ATP13A2 in the lysosomal membrane is predicted to be necessary for the 
elimination of aSyn aggregates and dysfunctional mitochondria via autophagy.  Cells deficient in DJ-1 












Figure 5.2 Knocking down ATP13A2 increases the accumulation of aSyn A53T in dopaminergic 
cells. 
MES 23.5 cells were transduced with A53T adenovirus +/- ATP13A2 shRNA lentivirus. The cells were 
harvested after 96 h, and cell lysates were analyzed via Western blotting (15 μg of protein per lane) using 
a primary antibody specific for aSyn (A, B) or ATP13A2 (C, D). Control MES 23.5 cells were untreated. 
Beta-actin was used as a loading control.  
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APPENDIX: LIST OF PRIMERS 
 
Primers used to generate DJ-1Δ15 variants in Chapter 2 and Chapter 3 
Human DJ-1 (Forward primer)  
 
5’CGAGCTCTCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATA
TG GCTTCCAAAAGAGCTCTGGT 3’ 
 
Human DJ-1Δ15 (Reverse primer) 
5’ CGAGCTCTCCTCGAGCTAGCCATTCAGGGCTTCAACAATTG 3’ 
 
 
Primers used for qRT PCR in Chapter 4  
Rat Park9 (Forward primer) 
 
5’ GCGTACACAGGGCATCTT 3’ 
 
Rat Park9 (Reverse primer) 
 
5’ GACCAGTGGCAGCAACAT 3’ 
 
Rat Park7 (Forward primer) 
 
5' GGAGAACAGGAAGGGCCTCATA 3' 
 
Rat Park7 (Reverse primer) 
 
5' GGGTGCGATGTAACCTTGCAT 3' 
 
Rat GAPDH (Forward primer) 
 
5' GAACATCATCCCTGCATCCA 3' 
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